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 The estrogen receptor-α (ERα) acts as a nuclear transcription factor to 
promote estrogen-induced transcription and plays a central role in the progression of 
ER-positive tumors. ERα binds to the consensus DNA elements referred to as 
Estrogen Response Elements (EREs) which act as enhancers mostly occupying 
distal regions. In our study, we show that Bromodomain-containing protein, BRD4 
depletion/inhibition regulates estrogen-induced transcription by affecting RNA 
polymerase II (RNAPII) and histone monoubiquitination in ER-positive MCF7 cells. 
Furthermore, BRD4 controls the proliferation of breast and endometrial cancer cell 
lines in vitro and estrogen-dependent uterine growth in vivo. Genome-wide studies 
demonstrate the increased occupancy of BRD4 near transcriptional start sites (TSS) 
upon estrogen stimulation and BRD4 inhibition decreases estrogen-stimulated H2B 
monoubiquitination across gene bodies substantially on the genes which display 
estrogen-induced de novo polymerase recruitment. Consistently, BRD4 binding 
correlates with active transcriptional marks on the promoters. Moreover, BRD4 also 
occupies ERα and FOXA1-bound distal elements after the appearance of ERα, 
H3K27ac and Cohesin. Interestingly, BRD4 inhibition regulates the RNAPII 
recruitment as well as phosphorylation on distal regions and inhibits the production 
of enhancer RNAs (eRNAs). Altogether these findings establish a specific 
coactivator function of BRD4 in estrogen-dependent transcription (Nagarajan et al., 
2014).  
 BRD4 binds to the acetylated chromatin preferentially on histone H4 at Lys 5, 
8, 12 and 16 residues. In our study, we also show that the presence of H4K12ac 
correlates with BRD4 occupancy during estrogen-driven transcription. Consistent 
with BRD4 binding, H4K12ac occupancy increases adjacent to estrogen-induced 
gene promoters and distal ERα-bound regions. H4K12ac is correlated with eRNA 
transcription and RNAPII occupancy on enhancers. Surprisingly, H4K12ac 
occupancy is increased in ER-positive cell lines compared to ER-negative cell lines 
and estrogen promotes global acetylation of H4K12ac in ER-positive cells. Notably, 
estrogen-induced H4K12ac occupancy is highly dependent on ERα expression and 
activity.  Altogether these findings confirm the importance of H4K12ac and BRD4 in 





potential therapeutic approaches for targeting histone acetylation and BRD4 in ERα-






1.1. Breast cancers and hormone dependency 
  Breast cancer is the second most frequently diagnosed cancer and the 
leading cause of cancer-related death in women reported in the global cancer 
statistics for the year 2012 (Ferlay et al., 2015). Occurrence of breast cancer is well-
correlated with lifestyle and is most prevalent in more developed regions of the 
world. Other than the environmental factors and lack of physical activity as being 
some of many risk factors, breast cancer can be hereditary and highly influenced by 
age and hormonal status in women.  
  Estrogen, which is a primary female sex hormone, plays an important role in 
the normal development of reproductive organs like breast, ovaries and uterus in 
women. It plays a central role in the development of the mammary gland during 
ductal elongation, side branching and lactational differentiation after puberty (Brisken 
and O’Malley, 2010). Dysregulation in its signaling can lead to development of breast 
cancer. The importance of hormones in breast cancers was initially identified due to 
the studies using ovariectomy (removal of ovaries) in an advanced breast cancer 
patient (Beatson, 1896). Moreover, the risk for breast cancer in women increases at 
the late menarche and early menopause stages reflecting the role of estrogen in 
cancer progression (Russo and Russo, 2006). Around two-thirds of breast cancers 
are estrogen receptor-positive. Estrogen mainly affects the proliferation of breast 
epithelial cells via promoting the transcription of various cell cycle-regulatory genes, 
which could act as tumor promoters and repressing genes, which negatively regulate 
cell proliferation (Cicatiello et al., 2010). Thus estrogen elicits its major endocrine 
effect by transcriptional regulation of gene expression.  
1.2. Estrogen receptor  
Estrogen mediates transcriptional activity via binding to the estrogen receptor 
(ER), which belongs to subfamily-3 of nuclear steroid receptors. ER acts mostly as a 
ligand-dependent nuclear transcription factor which can bind to DNA after estrogen 
activation and regulate transcription. Estrogen receptor exists as two isoforms 





gene. These isoforms are very similar in structure. Similar to ERα, ERβ is also 
shown to be important for the development of female reproductive organs, but its 
role in mammary glands is poorly established. In contrast to ERα, it is differentially 
distributed in tissues like testis, thymus, spleen and ovaries (Mosselman et al., 
1996). In the breast, expression and function of ERα is associated with epithelial 
cells and ERβ with stromal cells. Importantly in breast cancer cells, these receptors 
were also shown to possess opposite functions - where ERβ can inhibit ERα function 
(Omoto et al., 2003; Peng et al., 2003). Extensive research on ERα greatly allowed 
us to understand its role in the context of gene induction mechanisms in breast 
development and tumorigenesis (Green and Carroll, 2007).  
1.2.1. Structure of estrogen receptor 
The structure of estrogen receptor is conserved across various nuclear 
receptors (Sommer and Fuqua, 2001; Kumar et al., 2011). It possesses three 
structural domains: N-terminal domain (NTD), DNA-binding domain (DBD) and 
ligand-binding domain (LBD), where the functional domains of the receptor are 
referred to as A to H (Figure 1.1). The transcriptional activity of ER is determined by 
the presence of Activation Function domains AF1/2. Domains A and B are located in 
the NTD and constitute the AF1 domain, which functions in a hormone-independent 
manner. These domains also show high variability among all the steroid receptors. 
ERβ has a shorter NTD than ERα and displays only 15% homology in this domain. 
The DBD (C-domain) binds to DNA through its two zinc finger motifs. The first zinc 
finger located in the N-terminal region exerts an important function of allowing the 
nuclear receptor to bind to the consensus DNA sequence called the Estrogen 
Response Element (ERE) which consists of mostly a 13 bp palindromic motif 
GGTCAnnnTGACC. The second zinc finger regulates protein-DNA interactions 
which could be non-specific. ER further possesses a dimerization domain which 
allows it to form homo- or heterodimers after estrogen activation and bind to EREs. 
This domain importantly exerts more than 95% homology between ERα and ERβ. 
The D domain, otherwise called the hinge region contains a nuclear localization 
signal and also elicits coregulator binding property. E and F domains contain the 
LBD and are present in the C-terminal domain of the receptor. The LBD contains the 
structural pocket for the binding of estrogen and exhibits around 55% homology 





repressors to bind. The LBD also has various other important functional domains 
including a nuclear localization signal, a dimerization domain, and binding sites for 
coregulators and referred to as AF2. Therefore, this domain is considered to be very 
important for the estrogen-dependent transcriptional activity.  
 
Figure 1.1. Structure of estrogen receptor-α (ERα). The functional domains are shown according to 
their location and as A-F within brackets. The domains which interact with transcriptional coregulators 
are denoted with arrows as coregulator binding. Parentheses denote the activation function domains 
AF1 and AF2  (adapted from Sommer and Fuqua, 2001; Kumar et al., 2011).  
1.2.2. Mechanism of estrogen receptor-mediated transcription 
After estrogen stimuli, estrogen receptor executes the following subsequent 
processes to exert its transcriptional activity:  
 Receptor dimerization 
 Binding of the receptor to EREs 
 Recruitment of coactivators and histone-modifying enzymes 
Upon estrogen-activation, ERα undergo structural changes which promote 
dimerization. Reports show that ERβ can also heterodimerize with ERα (Cowley et 
al., 1997; Pace et al., 1997). Interestingly, ERα dominates its transcriptional role 
during heterodimerization with ERβ and this leads to the transcriptional activation 
(Cowley et al., 1997; Pace et al., 1997; Li et al., 2004). The resulting ERα homo- or 






1.2.2.1. Estrogen response elements 
The transcriptional activity of ERα is carried out by binding of the dimerized 
receptor to EREs after estrogen stimulation. These DNA elements are widely 
conserved among several vertebrates. Importantly, they act as transcriptional 
enhancers which could be present as regulatory elements frequently located far 
away from gene promoters. These regions are occupied with transcriptional 
coactivators and active histone marks and enhance transcriptional activation in a 
cell-specific manner (Heintzman et al., 2009; Heinz et al., 2015). These regions are 
particularly interesting in the context of ERα-regulated transcription as they are 
mostly distal. Only around 3-4 % of ERα binding sites occupy the promoter proximal 
regions or gene-bodies (Carroll et al., 2006; Li et al., 2013). The rest of them are 
located distal to gene promoters and appear to regulate the transcription of these 
genes. Distal ER binding sites are frequently considered as enhancers. Studies 
show that distal EREs influence the estrogen-induced transcription in an efficient 
manner comparing to EREs which are located close to the promoters (Pan et al., 
2008). Altogether these studies suggest that distal ERα binding sites function as 
bona fide enhancers to promote estrogen-responsive transcription.  
1.2.2.2. FOXA1 is a pioneer factor for ERα activity 
Pioneer factors are very important in facilitating ERα binding to ERE in a 
chromatin context. Pioneer factors are DNA binding proteins which can bind to the 
condensed chromatin efficiently and enable ATP-independent chromatin remodeling. 
The DNA binding domain of these proteins contains winged helices which resemble 
histone H1 (Clark et al., 1993). This allows the pioneer factors to bind to the major 
groove of DNA even in a condensed chromatin state. However, unlike histone 
proteins, these factors don’t compact the chromatin due to the absence of four basic 
amino acid sequences within the winged-helix domain compared to H1 and they 
associate with chromatin with their C-terminal domains binding to H3 and H4 
histones (Cirillo et al., 1998, 2002). Importantly, the Forkhead box-containing family 
of proteins (FOX) are among the predominant pioneer factors which determine tissue 
specific-transcription (Katoh and Katoh, 2004). FOXA factors were identified initially 
as activators of liver-specific gene expression in rat and hence also referred to as 





FOXA1 (HNF3α) was found to be associated with breast cancer prognosis 
and is predominantly expressed in luminal type A breast cancers. This has been 
implicated for ERα expression and activity (Nakshatri and Badve, 2007; Hu et al., 
2014). Moreover, FOXA1 is mutated or amplified as a focal region in 1.8% of breast 
cancers (Robinson et al., 2013). Reports using chromatin immunoprecipitation 
assays coupled with sequencing (ChIP-seq) confirmed the involvement of FOXA1 
protein in estrogen-regulated transcription (Hurtado et al., 2011). Motif analysis of 
estrogen receptor binding sites revealed an enrichment of FOXA1 binding motifs in 
regions bound by ERα. Around 50% of the ERα binding sites are also bound by 
FOXA1 in different ERα-positive breast cancer cell lines. Notably, upon depletion of 
FOXA1, ERα recruitment is significantly decreased on a large fraction of EREs 
identified in ERα-positive MCF7 breast cancer cells. Consistently, around 95% of 
estrogen-induced genes are affected by FOXA1 knockdown. These findings show 
that FOXA1 is required for the binding of ERα on the EREs and regulate estrogen-
mediated transcription. Other pioneer factors like PBX1, TLE, AP2γ and GATA3 can 
also associate with FOXA1 and influence ERα binding directly (Jozwik and Carroll, 
2012; Theodorou et al., 2013).  
Consistent with a role in promoting ERα activity, FOXA1 knockdown exhibited 
decreased estrogen-induced proliferation of ERα-positive cell lines. Tamoxifen 
belongs to the Selective Estrogen Receptor Modulator (SERM) family of drugs 
commonly used as a chemotherapeutic agent against ERα-positive breast cancers. 
Notably, 93% of tamoxifen-induced ERα binding sites in tamoxifen-sensitive cells 
overlap with those induced by estrogen. These sites also show the requirement of 
FOXA1 for the binding of ERα. Furthermore, around 55% of the unique ERα- binding 
sites in tamoxifen-resistant cells interestingly are co-occupied with FOXA1 and ERα 
binding requires FOXA1 in these regions. Consistently, overexpression of ERα and 
FOXA1 in ER-negative cells including the osteosarcoma cell line U2OS and ovarian 
cancer cell line OVCAR3 enable ERα binding to EREs bound in FOXA1/ERα-
positive cells. Moreover, FOXA1 maintains an open chromatin state for ERα to bind 
and ERα binding is less on the regions which are not already open and not bound by 
FOXA1. FOXA1 is also responsible for the maintenance of open chromatin on the 





important for determining overall ERα binding in ER+ cells and thus estrogen-
dependent transcription (Hurtado et al., 2011).  
1.2.2.3. Transcriptional coactivators of estrogen induction 
Upon binding to EREs, ER can recruit several transcriptional coregulators  
including the p160 family of coactivators, cAMP-response element-binding protein 
(CREB) binding protein (CBP), p300, p300/CBP-Associated Factor (PCAF), 
chromatin remodeling complexes like SWItch/Sucrose NonFermentable (SWI/SNF) 
complex or BRG1- or BRM-associated factors (BAF), histone methyltransferases like 
Coactivator-associated Arginine Methyltransferase-1 or Protein Arginine 
Methyltransferase-4 (CARM1/PRMT4) and PRMT1. The recruitment of these 
cofactors relies upon the activation function domains of ERα (Figure 1.2) (Sommer 
and Fuqua, 2001; Green and Carroll, 2007).  
AF1 and AF2 can regulate transcription independently as well as 
synergistically. Moreover, these domains determine the agonist or antagonist 
activities of anti-estrogens by associating with distinct transcriptional complexes in a 
context- and tissue-specific manner. Both of these domains exhibit binding with 
important transcriptional cofactors of estrogenic activity like Steroid Receptor 
Coactivator-1 (SRC-1) and exert cell type-specific activity. The structure of ERα LBD 
containing the AF2 domain and bound with 17 β-estradiol (estrogen-E2) or tamoxifen 
has been characterized (Wrenn and Katzenellenbogen, 1993; Green and Carroll, 
2007). This contains 12 α-helices named as H1-H12 and interestingly both estrogen 
and tamoxifen bind to the same helical pocket of ERα. However, upon estrogen 
binding, helices 3, 4, 5 and 12 undergo conformational changes to interact with 
proteins which contain LXXLL motifs including the p160 coactivators SRC1, 
amplified in breast cancer-1 (AIB1) or SRC3 and Glucocorticoid Receptor-Interacting 
Protein-1 (GRIP1) or SRC2. LXXLL motif is commonly called the nuclear Receptor 
Interaction Domain (RID). Contradictorily, when tamoxifen binds to ERα the helical 
pocket, helix H12 is placed in a conformation such that ERα no longer recognizes 
LXXLL-containing proteins, but interacts with proteins containing an LXXML motif 
(Shiau et al., 1998). This interrupts the interaction of ERα with p160 family of 
proteins and promotes ERα binding to transcriptional corepressors like Nuclear 





exhibits different structural changes which promote differential transcriptional activity 
in a ligand-specific manner.  
 
Figure 1.2. Association of pioneer factor and transcriptional cofactors in ERα-regulated 
transcription. Binding of FOXA1 on Estrogen Response Elements (EREs) facilitates the binding of 
ERα dimers which further leads to the recruiment of Histone Acetyltransferases (HATs), 
SWItch/Sucrose NonFermentable (SWI/SNF) complex and CARM1 to promote transcription. 
 Acetylation of histones appears to play a vital role of promoting transcriptional 
activation by recruiting several transcription factors and chromatin remodeling 
complexes. This further facilitates chromatin opening to promote transcription. 
Histone acetylation is mediated by Histone Acetyl-Transferases (HATs). Some of the 
notable HATs are CBP, p300 and PCAF. Interestingly, SRC1 also possesses 
intrinsic histone acetyltransferase activity (Spencer et al., 1997). These acetylate 
histones H3 and H4 at several residues and facilitate transcriptional activation. 
Importantly, CBP and p300 are involved in catalyzing histone acetylation which is 
associated with ERα-induced transcriptional activity. Recent cryo-electron 
microscopy studies validate the presence of p300 in the active ERα-coactivator 
complex (Yi et al., 2015). Furthermore, CBP/p300 and PCAF form a complex with 
p160 coactivators. This helps in the recruitment of the whole coactivator complex to 
EREs and induce estrogen-responsive transcription (Kamei et al., 1996; Korzus et 
al., 1998; Kim et al., 2001; Demarest et al., 2002). These factors can also interact 
with ERα in its AF1 and/or AF2 domain. Eventually, this facilitates their synergistic 
regulation of ERα-mediated transcription (Webb et al., 1998; Kobayashi et al., 2000). 
Moreover, acetylation of chromatin adjacent to estrogen-induced promoter of TFF1 
facilitates the binding of TATA box Binding Protein (TBP) which further recruits other 
transcription factors on promoters for activating transcription (Sewack et al., 2001). 
Importantly, CBP and p300 are shown to be highly expressed in breast cancers and 





breast cancer (Hudelist et al., 2003; Xiao et al., 2011). These factors along with p160 
proteins are also shown to be involved in ERα-dependent gene induction in 
tamoxifen-resistant breast cancers which express ER, Human Epidermal Growth 
Factor Receptor 2 (HER2/EGFR)and ERα-associated coactivator AIB1/SRC3 (Shou 
et al., 2004). All these findings demonstrate that HATs play an essential role in the 
activation of gene expression under estrogen-stimulation by interacting with ERα.  
 In addition to histone acetylation, histone methylation has a crucial function in 
ERα-induced transcription. Some of the histone methyltransferases methylate 
arginine residues on histones. For example, CARM1 was shown to methylate 
arginine residues 2, 17 and 26 of histone H3 (H3R2, H3R17 and H3R26), whereas 
PRMT1 was shown to methylate histone H4 at arginine 3 (H4R3). The role of these 
enzymes and their respective marks appears to be very important for estrogen-
regulated transcription (Bauer et al., 2002; Ma et al., 2001; Métivier et al., 2003; 
Schurter et al., 2001; Wagner et al., 2006). Furthermore, CARM1 was found to be 
recruited directly by ERα and p160 proteins and it cooperates with p160 and p300 
proteins to synergistically induce estrogen-stimulated transcription (Chen et al., 
1999, 2000). Importantly, during estrogen response,  CARM1 was also shown to 
recruit the SWI/SNF complex proteins (Brahma-Related Gene-1 (BRG1) and BRG1- 
or BRM-associated factor-57 (BAF57)) which can bind to acetylated chromatin to 
regulate chromatin remodeling (Xu et al., 2004). BRG1 and BAF57 are important for 
mediating estrogen-stimulated transcription due to their interaction with ERα-AF2 as 
well as with p160 cofactors (Belandia et al., 2002; García-Pedrero et al., 2006). All 
these studies establish the critical role of transcriptional cofactors and histone marks 
and understanding their importance would strengthen our knowledge on the 
molecular mechanisms involved in ERα-induced gene expression.   
1.2.2.4. Long range chromosomal interactions  
ERα primarily occupies regions distal to the promoters of estrogen-responsive 
genes and highly influences their transcription. This suggests that these enhancer 
and promoter regions are somehow linked to each other. Moreover, the presence of 
several enhancers near individual estrogen-regulated genes suggests that these 
regions can also be linked to each other despite of the linear distance between 





Recent technological advances in the analysis of long range chromosomal 
interactions improved the concept of chromosomal looping which is thought to be 
important in mediating enhancer and promoter interactions (Liu and Cheung, 2014). 
Variations of the Chromosomal Conformation Capture (3C) assay which utilizes the 
principle of proximity ligation supported the importance of enhancer-promoter 
interactions by DNA looping for several estrogen-responsive genes including 
CXCL12, PGR, SIAH2, GREB1, TFF1, CA12, P2RY2, ERBB2, CTSD and BCL2 
(Barnett et al., 2008; Bonéy-Montoya et al., 2010; Bretschneider et al., 2008; 
Dekker, 2006; Fullwood et al., 2009; Hurtado et al., 2008; Pan et al., 2008; Perillo et 
al., 2008; Prenzel et al., 2011, 2012; Theodorou et al., 2013; Zhang et al., 2010).  
ChIP coupled with 3C (ChIP-3C) experiments display that ERα is mainly involved in 
promoting long-range chromosomal interactions and estrogen and anti-estrogens 
stimulate and perturb intra-chromosomal loops respectively, to control the 
expression of NRIP1 and TFF1 (Carroll et al., 2005; Pan et al., 2008).  
Genome-wide studies of these long range interactions were facilitated by the 
development and implementation of Chromatin Interaction Analysis by Paired-End 
Tag Sequencing (ChIA-PET), which is an advanced version of the ChIP-3C assay. 
These studies show that ERα mediates long-range chromosomal interactions, 
where 86% of these regions were in the range of 10 to 100 kb, 13% in the range of 
100 kb to 1 Mb and < 1% longer than 1 Mb. The data from these studies also 
denote that there are several ERα-binding anchor regions which constitute complex 
interactions to regulate a single gene by promoting proximity with the promoter. 
These intra-chromosomal interactions were also partially verified by Fluorescence 
in-situ Hybridization (FISH) experiments. Around 60% of the estrogen-upregulated 
genes were found to be located between anchor regions and are associated with 
the occupancy of RNA polymerase II (RNAPII) across gene bodies. Interestingly, 
most of the estrogen-downregulated genes were observed in the looped DNA 
around the anchors around 20 kb or away (Fullwood et al., 2009). This could also 
explain a possibility of how estrogen receptor can differentially regulate gene 
expression.  
Notably, several transcriptional cofactors have been shown to be involved in 





promoter regions and thus facilitate the transcription of estrogen-dependent genes. 
ChIA-PET studies identified the role of a pioneer factor, Activating enhancer binding 
Protein 2 gamma (AP-2γ), to be involved in the regulation of ERα-dependent 
transcription via facilitating intra-chromosomal loops between different ERα binding 
sites (Tan et al., 2011). AP-2γ binds to AP-2 motifs adjacent to EREs and regulates 
estrogen-induced transcription. Furthermore, binding of ERα to EREs was found to 
be dependent on the recruitment of AP-2γ. Interestingly, depletion of AP-2γ highly 
perturbs estrogen-stimulated interactions between promoter-enhancer and 
enhancer-enhancer regions of the RET and GREB1 genes. Around 50% of the ERα 
binding sites are colocalized with AP-2γ which is similar to FOXA1 binding. 
Moreover, one-third of the EREs possess both FOXA1 and AP-2γ binding and 
approximately 14% of EREs are bound only by AP-2γ. These results further suggest 
that FOXA1 is not the only critical factor which is needed for ERα recruitment to 
EREs (Carroll et al., 2005; Jozwik and Carroll, 2012). Furthermore, the regions 
which were shown to be involved in the intra-chromosomal looping in the previously 
described ChIA-PET analyses (Fullwood et al., 2009) are mainly co-occupied by 
ERα, FOXA1 and AP-2γ (Tan et al., 2011). All these findings suggest the 
importance of FOXA1 and AP-2γ in mediating ERα-dependent long range 
interactions.  
Recently, GATA binding protein-3 (GATA3) was found to occupy EREs prior 
to FOXA1 binding and this controls the ability of ERα to mediate the chromatin 
looping (Theodorou et al., 2013). Depletion of GATA3 prior to estrogen treatment 
leads to a genome-wide redistribution in the binding of transcriptional cofactors and 
histone marks associated with gene activity. Upon GATA3 knockdown, ERα binds 
to distinct regions other than its consensus ERα binding sites. Moreover, GATA3 
alone facilitates intra-chromosomal interactions and affects TFF1 gene expression 
without the involvement of ERα.  
 Furthermore, recent studies elucidated the role of CCCTC-binding Factor 
(CTCF) and Cohesin in mediating long-range interactions in the context of estrogen-
dependent transcription (Schmidt et al., 2010). The CTCF protein is a highly 
conserved insulator protein and is associated with the maintenance of facultative 





architecture (Phillips and Corces, 2009; Narendra et al., 2015; Vietri Rudan et al., 
2015). In ER-positive cells, genome-wide studies show that CTCF binding is not 
affected by estrogen or tamoxifen treatment and functions prior to FOXA1 binding 
(Zhang et al., 2010; Ross-Innes et al., 2011). An interesting study using 3C assay in 
the TFF1 locus showed that CTCF acts as the upstream regulator prior to FOXA1 in 
the recognition of boundaries for the looping anchor regions which are not present in 
the estrogen-independent breast cancer cells. This would suggest a possibility that 
CTCF controls the cell type-specific occurrence of chromatin looping and specifically 
marks transcriptionally active regions (Zhang et al., 2010).  
 The Cohesin complex has been implicated not only in holding sister 
chromatids together during mitosis, but also in facilitating or maintaining 
chromosomal looping during interphase (Rhodes et al., 2011). Cohesin is made up 
of four subunits including Structural Maintenance of Chromosomes-1 and 3 (SMC1, 
SMC3), which together form a ring-like structure to link two or more chromatids, and 
RAD21 and Stromal Antigen-1 (STAG1) which form the basis of the ring structure. 
Various studies show that coordinated function of CTCF and Cohesin are involved in 
the regulation of insulator function across the chromosomes and thereby influence 
higher order chromatin looping (Rhodes et al., 2011). Notably, Cohesin recruitment 
is found to be increased after estrogen treatment on EREs specifically and also 
promotes the looping between distal regulatory regions (Li et al., 2013). Moreover, 
we showed that depletion of the Cohesin subunit SMC3 rapidly downregulates the 
expression of ESR1 (Prenzel et al., 2012). Interestingly, the regions which are co-
bound with ERα and Cohesin and not with CTCF mainly function in long-range 
interactions and regulate ERα-dependent transcriptional pathways (Schmidt et al., 
2010). Additionally, a minor subset of regions occupied with CTCF, ERα and FOXA1 
are bona fide enhancers of ERα-induced transcription (Ross-Innes et al., 2011). 
These studies show that CTCF and Cohesin complex can function distinctly 
according to the cell-specific scenarios in mediating chromosomal looping which 
could actively participate in transcriptional regulation. Furthermore, Mediator 
complex has been implicated both in transcriptional initiation as well as long-range 
chromosomal interactions together with the Cohesin complex in pluripotency and in  
estrogen-mediated transcription (Kagey et al., 2010; Prenzel et al., 2012; Allen and 





complex in facilitating intra-chromosomal interactions during estrogen-dependent 
gene induction.  
1.2.2.5. Transcription complex assembly and disassembly 
Estrogen receptor-mediated transcription involves complex and dynamic 
events in order to control transcription. Two important studies show that ERα-
induced transcription of TFF1 gene involves the association and disassociation of 
several transcriptional coactivators (Shang et al., 2000; Métivier et al., 2003). This 
results in a rapid increase and a dynamic decrease in transcription in order to 
efficiently respond to the estrogen stimuli. These transcriptional bursts contain six 
important phases which happen according to the duration of estrogen stimuli (Shang 
et al., 2000; Métivier et al., 2003; Green and Carroll, 2007).  
 Initially, pioneer factors like FOXA1, AP-2γ, GATA3 or CTCF bind to 
chromatin in order to denote the proper sites for ERα binding prior to estrogen 
treatment (I). During the response to estrogen treatment, prior binding of pioneer 
factors helps in the recruitment of ERα and p160 cofactors to promote transcription. 
HATs like p300, CBP and PCAF are also recruited by ERα and p160 factors to the 
EREs during this phase. This leads to histone acetylation (II). Subsequent 
recruitment of histone methyltransferases leads to histone methylation and RNAPII 
and its transcriptional cofactors are recruited to promoters which are brought in 
proximity to EREs by chromosomal looping to promote transcription. Additional HATs 
like General Control Nonderepressible-5 (GCN5) are also recruited to promote 
further acetylation on other specific residues (III). Increased acetylation and 
methylation lead to the efficient binding of the SWI/SNF complex proteins BRG1 and 
Brahma (BRM) to EREs as well as promoters. Altogether these events stabilize 
transcriptional activation. Over time, the expression of estrogen-induced genes can 
be reduced due to the decrease in the stimuli or the turn-over in the assembly of the 
activator proteins and the histone marks. The turnover of the activation complex is a 
rate-limiting step and is required for the activation of subsequent rounds of 
transcription. Furthermore, deacetylation by HDACs and demethylation by various 
histone demethylases are important to promote further acetylation and methylation 
for the next rounds of transcriptional response (IV). The next events occur at this 





cofactors (V). The cycle resumes as in phase III with subsequent histone acetylation 
and methylation (VI). Overall these events facilitate the dynamic assembly and 
disassembly of cofactors in order to stabilize the estrogen-induced transcription and 
to provide a temporal response for estrogen stimuli. Altogether, these also suggest 
that a rapid turnover of histone marks and cofactors are essential for regulating the 
transcriptional response in ERα-regulated gene expression.  
1.2.3. Dysregulation of estrogen receptor activity for breast cancer therapy 
ERα plays a central role in a large fraction of breast cancers. Expression of 
ERα predicts the response to hormonal therapies (Lumachi et al., 2013). Hence, 
ERα is the major therapeutic clinical target in ER-positive breast cancer. These 
cancers are treated by one of the following three endocrine therapeutic approaches: 
(i) ovarian suppression by the administration of gonadotropin-releasing hormone 
(GnRH) agonists, (ii) selective estrogen receptor modulators (SERMs) or 
downregulators and (iii) aromatase inhibitors which perturb estrogen production. 
ICI182780 or Fulvestrant is the only approved ERα downregulator for breast cancer 
patients. This compound rapidly promotes ERα degradation by the ubiquitin-
proteasome system (Wakeling and Bowler, 1992). Most commonly used drugs 
against ER-positive breast cancers are SERMs like tamoxifen and raloxifene. These 
drugs affect cell proliferation via their competitive binding to ER, induce different 
conformational changes in ER structure and promote transcriptional repression in 
breast cancer cells by recruiting repressors. Importantly, these inhibit ERα in a cell-
type specific manner. While tamoxifen and raloxifene inhibit the proliferation of ER-
positive breast cancer cells, they function like estrogen to preserve the bone mineral 
density. However, tamoxifen but not raloxifene activates the proliferation in other 
estrogen responsive tissues or organs such as the uterus. Thus, tamoxifen treatment 
has the major disadvantage of increasing the risk of endometrial cancer progression. 
Raloxifene has the advantage that it exhibits antiestrogenic activity on both the 
breast and uterus while acting estrogenic in the bone. Clinical trials showed that this 
drug can be used for patients with invasive breast cancers and osteoporosis as 
effectively as tamoxifen (Vogel et al., 2006).  
Although tamoxifen frequently shows positive effects on ERα-positive tumors, 





tumors over time. Several mechanisms were proposed to be important for the 
progression to tamoxifen resistance (Sommer and Fuqua, 2001). In tamoxifen-
resistant breast cancer cells, ERα and FOXA1 were shown to possess unique 
binding sites and their differential binding predicts the survival and metastatic status 
of the patients (Hurtado et al., 2011; Ross-Innes et al., 2012). In addition to the 
classical ligand-dependent activation of ERα by estrogen, ERα can also be activated 
by phosphorylation events via the signaling of growth factor receptors like 
EGFR/HER1, HER2, Insulin-like Growth Factor-I Receptor (IGF-IR), etc.,. During 
tamoxifen resistance, HER1-HER2 heterodimers and IGF-IR mediate ERα 
phosphorylation via Mitogen-Activated Protein kinase (MAPK) pathways. This 
thereby promotes the ability of ERα to regulate transcription (Lee and Yee, 1995; 
Tzeng and Klinge, 1996; Casa et al., 2008).  Moreover, these receptors promote cell 
proliferation by the activation of several downstream pathways like MAPK. 
Consistently, the expression of IGF-IR is correlated with the tamoxifen resistance in 
breast cancers (Nicholson et al., 2004). EGF induces distinct ERα binding to 67% of 
classical estrogen-induced binding sites while also inducing binding to other unique 
sites which are proposed to confer tamoxifen resistance to ER-positive tumors which 
overexpress HER2. The gene signature regulated by EGF-induced ERα is correlated 
with HER2 overexpression and with poor outcome in breast cancer patients  (Lupien 
et al., 2010). Tumors with estrogen receptor-positive/progesterone receptor-negative 
(ER+/PR-) which overexpress HER1/2 show robust resistance to tamoxifen and are 
more aggressive (Arpino et al., 2005). Thus, HER2 seems to be a critical 
determinant of tamoxifen resistance (Britton et al., 2006). Several mutations in ERα 
were also found to be associated with tamoxifen resistance. The mutations in the 
activator function domains or phosphorylation sites of ERα can lead to its constitutive 
activity in a ligand-independent manner thus driving tamoxifen resistance (Sommer 
and Fuqua, 2001; Lumachi et al., 2013).  
However, 1/3 of the breast cancers are not driven by ERα. Reports show that 
the triple negative breast cancers (lacking expression of ERα, PR and HER2) have 
poor overall and disease-free survival rates whereas ER+/PR+ cancers have a better 
survival rate (Onitilo et al., 2009). The similar observation was also found with 
FOXA1 status where ER-/FOXA1- patients possess 3.6% increased risk of cancer 





2009).  This suggests that ERα status is an indicator of the overall response for 
endocrine therapy and decreased risk in the progression of aggressive tumors, and 
dysregulation of ERα can lead to a poorer prognosis. However, the normal and 
tumorigenic activity of ERα seems to possess contradictory roles in mammary 
epithelium and breast cancer development. Considering the importance of ERα-
driven transcription in the proliferation and hormone dependency/independency in 
breast cancer, an extensive understanding of the molecular mechanisms of the ERα-
mediated transcriptional pathways can help in the discovery of potential specific 
therapeutic targets against breast cancers.  
1.3. Nucleosomal organization and histone modifications  
Gene transcription is highly influenced by the organization of DNA into 
chromosomes. The DNA of a human cell covers approximately 2 meters of length. 
However, this DNA becomes highly condensed and organized in order to fit into the 
nucleus by associating with histone proteins. Histones belong to highly conserved 
proteins which exist in five different types H1, H2A, H2B, H3 and H4. Two H2A-H2B 
and H3-H4 heterodimers form a nucleosomal core particle by forming an octamer 
covering 147 bp of DNA and H1 binds to the linker DNA between each nucleosome. 
Higher order organization of the nucleosomes leads to highly condensed chromatin 
and chromosomes (Luger et al., 1997; Ramakrishnan, 1997). Interestingly, histone 
proteins, in general, elicit major topological and functional effects which influence 
transcriptional status (Mariño-Ramírez et al., 2005).  
1.3.1. Histone code and cross-talk 
Histone proteins undergo various post-translational modifications like 
acetylation, methylation, phosphorylation, ubiquitination, etc., These marks are highly 
implicated in the coordinative regulation of transcription along with transcription 
factors. The presence of various histone marks is correlated with an active or 
repressed transcriptional status and are described as active marks or repressive 
marks respectively (Zhou et al., 2011; Shlyueva et al., 2014) (Figure 1.3). For 
example, histone trimethylation on H3 at Lys 4 (H3K4me3) is described to be 
involved in the active transcription marking the active promoters while 





(H3K27ac) serves as an active mark for both promoters and enhancers whereas 
methylation of Lys 27 (H3K27me3) is linked with transcriptional repression. 
Furthermore, several marks like H3K36me3, H3K79me3 and H2B 
monoubiquitination (H2Bub1) are correlated with transcriptional elongation. The 
diverse functions of histone modifications highly support the establishment of histone 
marks-mediated cross-talks. This has led to the histone code hypothesis which 
states that the presence of various different histone modifications is associated with 
and influences the transcriptional activity of the genome (Strahl and Allis, 2000; 
Jenuwein and Allis, 2001). Notably, several histone marks have been shown to be 
associated with estrogen-induced transcription.  
 
Figure 1.3. Commonly studied histone modifications and their correlation with transcriptional 
activation or repression. Marks which are marked with green are considered as active and red as 
repressive marks of transcription. Elongation-associated marks are mentioned adjacent to the 
promoter in the direction of transcription.  
1.3.2. Histone acetylation in estrogen induced transcription 
Histone acetylation is generally associated with active transcription. Histone 
acetylation facilitates the activation of transcription largely by recruiting several 
sequence-specific transcriptional factors and chromatin remodeling complexes 
(Allfrey et al., 1964; Grunstein, 1997; Struhl, 1998; Clayton et al., 2006). This 
modification is catalyzed by HATs and removed by Histone Deacetylases (HDACs). 
In various contexts, histone acetylation and deacetylation have been shown to be 
important for fine tuning the transcriptional activity and for temporal response in 
stimuli-induced transcription, especially in estrogen-mediated transcription (Kim et 
al., 2001; Sun et al., 2001). Several HATs are identified as transcriptional 





assembly of transcription complexes along with ERα (Shang et al., 2000; Métivier et 
al., 2003; Green and Carroll, 2007; Yi et al., 2015). These interact with ERα to form 
an active complex which leads to induced histone acetylation after estrogen 
treatment (Kim et al., 2001; Sun et al., 2001; Yi et al., 2015).  
Histone deacetylation was also shown to regulate estrogen receptor-
dependent transcription and has been suggested as a potential target for 
combination therapy together with anti-estrogens. For instance, several  HDAC 
inhibitors downregulate the expression of ERα and sensitize the cells to tamoxifen 
treatment (Hodges-Gallagher et al., 2006; Biçaku et al., 2008; Thomas et al., 2011). 
However, in ER-negative breast cancer cells, administration of HDAC inhibitors, 
LBH589 and entinostat, reactivates ERα expression by releasing the binding of 
DNMT1 (DNA methyltransferase-1), H3K9 methyltransferase SUV39H1 and HDAC1 
from the ESR1 promoter and restores sensitivity to tamoxifen and aromatase 
inhibitors (Zhou et al., 2007; Sabnis et al., 2011). Furthermore, use of Vorinostat, 
another HDAC inhibitor, may be effective in patients who developed resistance 
against tamoxifen (Munster et al., 2011). Furthermore, HDAC inhibition by PCI-
24781 kills breast cancers cells by downregulating the expression of AKT and thus 
inhibiting hormone-independent activity of ERα (Thomas et al., 2013).   
Association of histone acetylation also occurs on on ERα-bound enhancers. In 
particular, H3K27ac is associated with active promoters and enhancers. 
Interestingly, this mark occupies found to occupy 23% of ERα-bound enhancers 
along with H3K4me1 (Li et al., 2013). Several studies demonstrated an increase of 
H3K27ac upon estrogen treatment at ERα binding sites (Lupien et al., 2009; Hah et 
al., 2013). Additionally, marks like H3K18ac and H4K12ac were also shown to be 
increased on EREs after estrogen treatment (Lupien et al., 2009). These were also 
upregulated on the EGF-responsive ERα binding sites, supporting a role in the 
ligand-independent function of ERα and in hormone-refractory breast cancers 
(Lupien et al., 2010). Furthermore, H4K12ac is recognized by Bromodomain-
containing protein BRD4, which belongs to the  bromodomain and extraterminal 
domain (BET) containing family of proteins, and recently implicated in tamoxifen-






1.3.3. Epigenetic readers and BRD4  
Transcriptional activation is facilitated by histone acetylation (Allfrey et al., 
1964; Grunstein, 1997; Struhl, 1998; Clayton et al., 2006). Several histone-modifying 
complexes and chromatin-remodeling factors bind to the acetylated chromatin 
through specific protein domains called bromodomains. These domains were initially 
identified from a protein Brahma which belongs to Drosophila SWI/SNF complex and 
binds to acetylated lysine residues of histone tails (Tamkun et al., 1992). 
Bromodomains are highly conserved and are interestingly found in many HAT 
proteins including PCAF, TAFII250, CBP/p300 and GCN5 (Muller et al., 2011; 
Filippakopoulos and Knapp, 2014; Hohmann and Vakoc, 2014). Thus, in addition of 
containing acetyltransferase activity, HATs frequently possess bromodomains which 
bind to acetylated chromatin and further promote additional acetylation events. 
Moreover, some transcriptional co-activators including bromodomain-containing 
proteins BRD2/3/4/T and subunits of chromatin remodeling SWI/SNF complex 
including Brg1, Brm, BRD7 and BRD9 also possess bromodomains. Among these 
proteins, double bromodomain containing protein, BRD4 and SWI/SNF complex 
proteins are currently recognized as the potential therapeutic targets against various 
cancers.  
Apart from its association with mitosis, BRD4 has mainly been studied for its 
role in transcription by regulating promoter and enhancer activity by binding to 
acetylated histone H4 at Lys 5,8,12 and 16 residues (Chiang, 2009; Zippo et al., 
2009; Zhang et al., 2012a; Lovén et al., 2013). Recent evidence suggests that BRD4 
recognizes poly-acetylated and phosphorylated histones in adjacent residues with an 
higher affinity than single acetylated sequences (Filippakopoulos et al., 2012). This 
study also showed that specificity of each bromodomain for recognizing acetylated 
residues is different between bromodomains within the same protein, where the first 
bromodomain (BD1) of BRD4 preferentially binds to poly-acetylated histone peptides 
of H4K5, 8, 12 and 16 while the second bromodomain (BD2) binds preferentially to 
acetylated H4K12 and 16 and histone H3. This suggests a strong cross-talk between 
adjacent histone acetylation and phosphorylation marks which regulate binding of 






1.3.3.1. Structure of BRD4 and development of BRD4 inhibitors 
 BRD4 is the prototype of the BET family of proteins which contains two 
bromodomains, an extra-terminal domain and a C-terminal Positive Transcription 
Elongation Factor-b (P-TEFb) interaction domain (PID) (Figure 1.4). BRD4 exists as 
two different isoforms including a full-length transcript and a shorter form which lacks 
the PID (Chiang, 2009). Among these domains, the bromodomains are functionally 
important for BRD4 to elicit its transcriptional activity via binding to acetylated lysine 
residues of histones thereby facilitating BRD4 recruitment to chromatin. Additionally, 
the extra-terminal domain promotes protein-protein interactions with several 
transcription factors and histone modifiers including the Chromodomain and 
Helicase-containing protein CHD4 which belongs to the Nucleosome Remodeling 
and Deacetylase (NuRD) complex, RNA splicing-associated Jumonji-domain 
containing histone demethylase JMJD6, H3K36 methyltransferase NSD3 or 
WHSC1L1,  GLTSCR1 which is a tumor  suppressor, and ATAD5 which might be 
involved in ATM/ATR-driven DNA damage response (Rahman et al., 2011; Liu et al., 
2013). The PID domain of BRD4 plays an essential role in transcription via its 
interaction with P-TEFb. However, recent studies show that bromodomains can also 
interact with acetylated P-TEFb complex proteins (Schröder et al., 2012). 
Triacetylated Cyclin T1 was shown to interact with bromodomains, however it also 
requires interaction with PID for its activation.  
 The evolutionarily conserved bromodomain is made up of four helices αZ, αA, 
αB and αC. These helices are linked by two loops called as ZA and BC which are 
similar in charge and amino acid length. These surround the acetyl-lysine binding 
pocket, which is hydrophobic and binds to chromatin via interaction with its 
conserved Asn residue. Interestingly, a recent study demonstrate the association of 
two acetyl-lysine residues with a single bromodomain (Morinière et al., 2009; 
Filippakopoulos et al., 2012; Filippakopoulos and Knapp, 2014). Structural and 
biochemical analyses on BD1 of BRDT describe that after the anchoring of the first 
acetyl-lysine residue to the hydrophobic pocket, hydrogen bonds form a network with 
the second acetyl-lysine moiety. Subsequent binding of two acetyl-lysine residues 
determines the specificity of BRD4 to bind to particular histone acetylation and 





Even though the structure of bromodomains is highly similar among its family of 
proteins, the regions covering the surface of the pocket and loops are highly variable 
which enables the development of specific inhibitors against individual 
bromodomain-containing proteins.  
 
Figure 1.4. Structure of BRD4 with its interacting proteins. BD1 and BD2 represent first and 
second bromodomains respectively. ET – Extra-Terminal domain; PID – P-TEFb Interaction Domain. 
NPS – N-terminal Cluster of Phosphorylation Sites. The regions of BRD4 where various 
transcriptional cofactors interact with are shown with arrows (Modified from  Schröder et al., 2012). 
 Various small molecule inhibitors against BET family of proteins with high 
affinity towards BRD4 have been reported. These competitively bind to the acetyl-
lysine binding pocket of BRD4 and displace BRD4 from the chromatin and inactivate 
its function in transcriptional regulation. They function by mimicking the acetyl-lysine 
residue in forming hydrogen bonds with Asn residue of the hydrophobic pocket of the 
bromodomain (Filippakopoulos et al., 2010). The acetyl-lysine mimics belong to the 
chemical structure-based classes of thienodiazepines (for e.g. JQ1, OTX015) 
(Filippakopoulos et al., 2010; Coude et al., 2013), benzodiazepines (I-BET762 or 
GSK525762A) (Mirguet et al., 2013), benzotriazepine (I-BET151) (Dawson et al., 
2011), dihydroquinazoline-one (PFI-1) (Picaud et al., 2013a), quinazolone (RVX-208) 
(Picaud et al., 2013b), etc., (Filippakopoulos and Knapp, 2014).  The most commonly 
used BRD4 inhibitor in transcriptional research is JQ1 (Filippakopoulos et al., 2010). 
This inhibitor is used commonly as a highly specific BET domain inhibitor against 
BRD1/2/3/4/T; however it binds to the acetyl-lysine binding pockets of both BD1 and 





the research groups of Bradner and Knapp have rapidly facilitated a large number of 
studies using JQ1 in the potential treatment of various diseases including cancer 
(Muller et al., 2011; Barbieri et al., 2013; Filippakopoulos and Knapp, 2014).  
1.3.3.2. BRD4 in regulating gene transcription 
Activation of transcription by BRD4 requires an extensive histone cross-talk. 
Binding of BRD4 to the chromatin is facilitated by the coordination of acetylation and 
phosphorylation events on histones (Filippakopoulos et al., 2012). A cross-talk 
mediated by H3S10ph which leads to gene activation in trans was established for the 
FOSL1 gene upon serum induction (Figure 1.5) (Zippo et al., 2009). In order to 
respond to serum induction, a number of dynamic events occur in the chromatin 
context. Initially, H3S10ph is stimulated on the FOSL1 promoter and enhancer 
regions. Depending upon the context, phosphorylation on these regions can be 
catalyzed by different kinases. Promoter-occupied H3S10ph is mediated by MSK1/2 
and enhancer-associated H3S10ph by PIM-1. This subsequently provides a 
phospho/acetyl platform in the chromatin. The acetyl-phosphorylation on enhancers 
specifically induces the recruitment of 14-3-3 proteins which promotes the binding of 
a histone acetyltransferase, Males absent On the First (MOF). As a result, MOF 
acetylates H4K16ac leading to serum-stimulated acetylation on enhancers. This, in 
turn, allows efficient BRD4 binding to the chromatin.  
A number of studies describe the binding of BRD4 on enhancers as well as 
promoters, but the possibility of BRD4 in bringing these regions proximal to each 
other via chromosomal looping is still not clear (Liu et al., 2013). Importantly, the 
association of BRD4 with acetylated chromatin recruits P-TEFb to the chromatin and 
this enables transcriptional activation. P-TEFb complex contains Cyclin-Dependent 
kinase (CDK9) and Cyclin T1/T2 and in most cases, this is associated with an 
inactive complex containing the 7SK small nuclear ribonucleoprotein complex, La 
Related Protein-7 (LARP7) and HEXamethylene bisacetamide Inducible protein 
(HEXIM) proteins. Further biochemical analyses of BRD4 and P-TEFb interaction 
suggest that BRD4 efficiently interacts with P-TEFb via its second bromodomain 
BD2 and PID and interaction with PID releases P-TEFb from the inactive complex. 
Thus, active P-TEFb associates with chromatin via interaction with BRD4 (Ai et al., 





P-TEFb elicits its positive effect on transcription via CDK9-mediated 
phosphorylation of Negative Elongation Factor (NELF), Suppressor of Ty 5 
Homolog-5 (SUPT5H) and serine 2 of the RNAPII C-terminal tail in their heptad 
repeats. SUPT4H and SUPT5H constitute the 5,6-Dichloro-1-beta-D-
ribofuranosylbenzimidazole (DRB) Sensitivity-Inducing Factor (DSIF) and are 
associated both with paused polymerase as well as active transcription. Importantly, 
NELF is involved in the pausing of RNAPII around 40 bp proximal to the promoter 
regions. This event is referred as promoter proximal pausing of RNAPII and is 
proposed to affect the efficient transcription of full-length transcripts. Hence, NELF, 
when bound to DSIF, inhibits the positive function of SUPT5H on transcription. 
Phosphorylation of the NELF-E subunit by CDK9 releases NELF from the chromatin 
and allows SUPT5H to exhibit its positive role on transcription activation (Yamaguchi 
et al., 1999; Ping and Rana, 2001; Peterlin and Price, 2006; Patel et al., 2013). 
Interestingly, the HEXIM and NELF complex proteins have been shown to regulate 
estrogen-induced transcription (Aiyar et al., 2004; Ogba et al., 2008; Ketchart et al., 
2011).  
 
 Figure 1.5. Regulation of BRD4 and histone marks in coordinating transcriptional activation. 
MOF - Males absent on the First; BRD4 – Bromodomain-containing protein-4; P-TEFb – positive 
Transcription Elongation Factor b; RNAPII – RNA Polymerase II; S2P – RNAPII Serine 2 
phosphorylation; SWI/SNF - SWItch/Sucrose NonFermentable complex.  
Phosphorylation of RNAPII at serine 2 residues (RNAPII PSer2) within its C-
terminal heptapeptide repeats is associated with transcriptional elongation. This 
further serves to promote histone H2B monoubiquitination which facilitates opening 





2008; Pirngruber et al., 2009a, 2009b). Moreover, H2Bub1 further controls the 
recruitment of Mixed Lineage Leukemia Complex of Proteins Associated with Set 1 
(MLL/COMPASS) complex to promote H3K4me3, potentially providing an additional 
mechanism for its role in transcriptional activation (Dover et al., 2002; Johnsen, 
2012).  
Additionally, in the context of ERα-regulated transcription in tamoxifen-
resistant breast cancers, BRD4 was reported to recruit WHSC1, which helps in the 
methylation of H3K36, further associating with transcriptional elongation (Feng et al., 
2014). Moreover, another recent study uncovered an interaction of BRD4 with 
SWI/SNF complex subunits and BRD4 inhibition by JQ1 or BRG1 depletion both 
regulated the expression of a subset of genes via their recruitment to chromatin in an 
independent manner (Shi et al., 2013). Thus, activation of BRD4 requires the 
coordination of acetylation and phosphorylation and this subsequently leads to 
ubiquitination and methylation of histones and the recruitment of transcription-
associated proteins to favor transcription.  
Several recent studies have shown that BRD4 inhibition by JQ1 reverses the 
effects of dysregulation of various cell and lineage-specific transcription-factor 
associated pathways like p53, NF-κB, GATA4, Calcineurin-NFAT, c-MYC, etc., 
(Delmore et al., 2011; Ott et al., 2012; Wu et al., 2013; Anand et al., 2013; Zou et al., 
2014). Furthermore, a direct interaction of p53 and NF-κB with BRD4 was also 
studied (Wu et al., 2013; Zou et al., 2014).  
The acetylation of the Rel-A subunit of NF-κB was shown to be recognized by 
the bromodomains of BRD4. This stabilizes NF-κB and its activity and is important 
for NF-κB-driven transcription during tumorigenesis in lung cancer cells (Zou et al., 
2014). Recent biochemical studies on the interaction of BRD4 and p53 identified two 
novel domains in BRD4 called as N-terminal cluster of Phosphorylation Sites (NPS) 
which contains putative phosphorylation sites and Basic Interaction Domain (BID) 
with several conserved basic amino acids (Wu et al., 2013). These domains are 
located downstream of BD2 of BRD4. The NPS contains several acidic residues and 
tends to interact with the positively charged BRD4-BD2. This competitively interrupts 
the binding of BD2 to the chromatin. Moreover, p53 association with chromatin is 





phosphorylation of NPS leads to an intramolecular contact switch of interaction from 
NPS-BD2 to NPS-BID. This subsequently allows the BD2 to associate with 
chromatin and also leads to the binding of p53 to NPS. Thus, this phosphorylation-
dependent switch in BRD4 facilitates p53-dependent transcription. These studies 
further denote that the association of BRD4 with transcription factors is essential for 
BRD4-assisted transcriptional activation. 
1.3.3.3. BRD4 in cancer 
 BRD4 was initially identified via its association with cancer in NUT midline 
carcinoma (NMC) which affects adjacent parts of the respiratory tract (French et al., 
2001). This is a highly aggressive and poorly differentiated cancer with 75% of cases 
possessing a translocation of BRD4 (t(15;19)) with the Nuclear protein in Testis 
(NUT) gene leading to the transcription of a BRD4-NUT fusion protein. This 
promotes tumorigenesis by interrupting the differentiation of epithelial cells. BRD3-
NUT and BRD4-NUT depletion in these cells led to squamous cell differentiation and 
cell cycle arrest (French et al., 2008). The importance of BRD4 in the progression of 
several cancers like leukemia, lymphoma and solid tumors have also been studied 
(Zuber et al., 2011; Herrmann et al., 2012; Lockwood et al., 2012; Chapuy et al., 
2013; Asangani et al., 2014; Bhadury et al., 2014; Feng et al., 2014; Fiskus et al., 
2014; Sahai et al., 2014; Wang et al., 2015; Hu et al., 2015; Baratta et al., 2015).  
 Notably, BRD4 has been implicated in the progression of breast cancer. 
Xenograft studies of mouse mammary tumor cell lines which contain a deletion of C-
terminal proline-rich region containing the PID of Brd4 promoted metastasis and 
stem cell-like conversion (Alsarraj et al., 2011). Consistently, overexpression of Brd4 
led to reduced invasiveness and pulmonary metastasis and decreased tumor growth 
(Crawford et al., 2008). Brd4 deletion also promoted the expression of a subset of 
genes which is associated with poor outcome in human breast cancer, especially G3 
grade tumors (Alsarraj et al., 2011). Consistently, a deeper analysis of BRD4-
regulated gene signatures also predicted better survival and outcome in breast 
cancer patients, particularly ER-positive breast cancers. Furthermore, a recent study 
demonstrated that BRD4 is a central transcriptional coactivator for androgen 
receptor-induced transcription in castration-resistant prostate cancer, which supports 





Consistently, BRD4 was shown to be essential for ERα-dependent transcription 
induction in tamoxifen-resistant breast cancers (Feng et al., 2014). Thus, 
understanding the molecular mechanism behind the association of BRD4 with 
estrogen-induced transcription is essential for the potential establishment of BRD4 
as a specific therapeutic target for ERα-positive breast cancer.  
1.3.4. Histone ubiquitination in breast cancer 
Histone modifications are coordinated with one another to facilitate a given 
transcriptional outcome. They provide a specific platform for the binding of 
transcription factors which control transcription. However, significant topological 
changes of chromatin structure also occur during transcription. One of the 
modifications which influences chromatin organization is histone H2B 
monoubiquitination. H2Bub1 occurs at lysine 123 in yeast and lysine 120 in 
mammals and introduces an 8.5 kD ubiquitin moiety into the chromatin which 
appears to physically open the chromatin structure (Fierz et al., 2011; Johnsen, 
2012).  
H2B monoubiquitination has been shown to be associated with transcriptional 
elongation and occupy gene bodies (Pavri et al., 2006; Minsky et al., 2008). This 
modification is mediated by the obligate heterodimeric E3 ubiquitin ligase complex 
RNF20/40.  Recruitment of RNF20/40 complex and H2Bub1 occupancy is facilitated 
by P-TEFb complex (Pirngruber et al., 2009a). The kinase activity of CDK9 promotes 
phosphorylation of RNAPII at Ser2 residues which serves as an active mark for 
transcriptional elongation and provides a specific platform for an adaptor protein, 
WW domain-containing adapter protein WAC (Zhang and Yu, 2011). The WW 
domain present in the N-terminal tail of WAC directly recognizes CDK9-mediated 
RNAPII Ser2P while the C-terminal coiled coil domain directly interacts with the 
RNF20/40 complex. Subsequently, this leads to H2B monoubiquitination (Pirngruber 
et al., 2009a; Karpiuk et al., 2012).  These show that the P-TEFb complex functions 
together with RNF20/40 complex to promote histone monoubiquitination to facilitate 
transcriptional elongation.  
A number of studies have suggested a role of P-TEFb and H2B 





al., 2005; Ogba et al., 2008; Ketchart et al., 2011; Prenzel et al., 2011; Mitra et al., 
2012; Sengupta et al., 2014). Notably, CDK9 and Cyclin T1 were shown to form a 
complex with ERα which is further increased after estrogen treatment (Sharp et al., 
2006; Mitra et al., 2012). This complex was also shown to release the transcriptional 
pausing of the estrogen-dependent MYB proto-oncogene. Consistently, flavopiridol 
(a relatively specific CDK9 inhibitor) and DRB inhibit MYB expression (Mitra et al., 
2012). Induced expression of another estrogen-responsive oncogene MYC is 
associated with tamoxifen-resistant cell lines. Interestingly, the expression of CDK9 
is also elevated in these cell lines, where it was shown to promote RNAPII PSer2 in 
on the MYC gene and thereby facilitate estrogen-independent proliferation 
(Sengupta et al., 2014).  
In addition to these findings, Cyclin T1 was also reported to interact with ERα 
where its activity is negatively regulated by HEXIM1, which is a component of the 
inactive 7SK/P-TEFb complex (Wittmann et al., 2005). Estrogen-induced 
transcription of TFF1 and CCND1 is inhibited by HEXIM1 (Ogba et al., 2008). 
Moreover, HEXIM1 recruitment is increased during tamoxifen treatment to inhibit 
ERα-responsive transcription and its lower expression is associated with tumor 
recurrence after tamoxifen treatment, indicating a potential role in tamoxifen-resistant 
breast cancer (Ketchart et al., 2011). Consistently, Ser2-phosphorylation of  RNAPII 
is important in the dynamic events of estrogen-induced transcription by regulating 
transcriptional elongation (Kininis et al., 2009). Altogether these studies suggest the 
physical and functional interaction of P-TEFb complex with ERα to be essential for 
the regulation of estrogen-responsive transcription. 
Notably, H2Bub1 was shown to be important for estrogen-induced 
transcription (Prenzel et al., 2011). In this study, RNF40 depletion reduced the 
expression of estrogen-induced genes CXCL12, GREB1 and TFF1. These studies 
demonstrate that the inhibition of proteasomal activity regulates estrogen signaling, 
most likely via depletion of nuclear ubiquitin pool. This further results in a rapid loss 
of H2Bub1 which affects estrogen-induced transcription. Furthermore, RNF20 has 
been suggested to be a potential tumor suppressor. RNF20 depletion increases the 
EGF-induced migration of breast epithelial cells. RNF20 promoter hypermethylation 





2008; Prenzel et al., 2011). Consistent with the finding of yeast SPT6 being a 
transcriptional activator of ERα-dependent transcription (Baniahmad et al., 1995), a 
recent study showed that SUPT6H promotes H2B monoubiquitination and estrogen-
stimulated transcription (Bedi et al., 2015). This study demonstrated that SUPT6H is 
required for the expression of RNF40 and forms a complex with both RNF40 and 
ERα. Consistently, SUPT6H protein levels correlated positively correlated with 
H2Bub1 levels and inversely with breast cancer malignancy.  
A recent interesting report reveals that SWI/SNF complex, which is also 
shown to be important for estrogen-regulated transcription, can bind to H2Bub1 
modified chromatin directly and its recruitment depends upon RNF20 (Shema-
Yaacoby et al., 2013). Moreover, this study shows that the expression of H2Bub1-
dependent genes is regulated by the SWI/SNF complex. This is consistent with the 
interaction of BRD4 and SWI/SNF complex to regulate the expression of a similar 
subset of genes (Shi et al., 2013). Thus, BRD4, H2Bub1 and the SWI/SNF complex 
may cooperate in estrogen-stimulated transcription.  
1.4. Enhancer RNAs in regulating transcription 
 The regulation of mRNA expression by enhancers is coordinated by long-
range chromosomal interactions, enhancer-associated histone modifications and 
transcriptional machinery which can function to link enhancers with promoters. 
Interestingly, enhancer transcription was discovered recently and shown to be 
essential for enhancer activity. These non-coding transcripts are referred to as 
enhancer RNAs (eRNAs) (Lam et al., 2014). Widespread transcription of eRNAs was 
recently observed via the advancement in the nuclear run-on assays and a few 
studies demonstrate the characteristics of eRNAs (Kim et al., 2010; Li et al., 2013). 
eRNAs typically range in size from 500 to 5000 bp and could be transcribed in both 
directions (Li et al., 2013). These transcripts are dynamically associated with 
promoting mRNA expression in various cell-specific contexts, especially in androgen 
and estrogen-responsive transcription (Kim et al., 2010; Wang et al., 2011; Hah et 
al., 2013; Li et al., 2013; Kaikkonen et al., 2013; Hsieh et al., 2014; IIott et al., 2014; 





 The transcription of enhancer RNAs is correlated with the occupancy of 
RNAPII on the promoters which are looped to enhancers via long-range interactions 
and could thus represent transcriptional noise (Natoli and Andrau, 2012; Lam et al., 
2014). Several studies were conducted to understand the functions of eRNA in the 
context of mRNA transcriptional regulation. A classical Locus Control Region (LCR), 
which has more recently been described as a “super enhancer”, constitutes a set of 
enhancer regions controlling a single gene expression. A DNase Hyper-Sensitivity 
site HS2 which is located within the LCR of β-globin gene was shown to be important 
for the enhancer activity of LCR. Interestingly, this site possesses a transcriptional 
start site and the introduction of a lac operator/R repressor complex downstream of 
HS2 in a reporter construct blocks its enhancer activity (Tuan et al., 1992; Ling et al., 
2004). Furthermore, insertion of a transcriptional termination site into the LCR of the 
human Growth Hormone (hGH) gene also regulates hGH expression (Ho et al., 
2006).  
Recent evidences further verified the importance of eRNAs in the 
transcriptional regulation of estrogen-responsive transcription (Hah et al., 2013; Li et 
al., 2013). Notably, estrogen-induced eRNAs were identified in MCF7 cells from 
parallel studies by Rosenfeld and Kraus groups (Hah et al., 2013; Li et al., 2013). 
eRNA transcription was shown to be dependent upon ERα binding to EREs. 
Furthermore, utilization of chimeric eRNA designed to bind to an estrogen-induced 
promoter specifically shows that the presence of the eRNA transcript is essential for 
the stimulation of estrogen-induced transcription of the cognate target gene. 
Moreover, specific estrogen-induced eRNA depletion using small interfering RNAs 
(siRNAs) or Locked Nucleic Acids (LNA) regulates the transcription of respective 
estrogen-driven genes. This study also shows that eRNAs induce estrogen-induced 
chromatin looping and the Cohesin complex physically stabilizes the looping by its 
interaction with eRNA (Li et al., 2013).  
Lee Kraus and his colleagues (Hah et al., 2013) showed that estrogen-
upregulated eRNAs are associated with enhancer-specific active transcriptional 
complexes including ERα, FOXA1, p300/CBP, RNAPII which demonstrate DNase 
hypersensitivity, histone marks like H3K27ac and H3K4me1 and estrogen-induced 





novo enhancer activity (Kaikkonen et al., 2013). The kinetics of eRNA transcription 
was shown to occur very rapidly supporting the dynamic nature of estrogen-induced 
transcription. Importantly, flavopiridol treatment inhibited eRNA synthesis without 
affecting the formation of the initial active transcriptional complex forming events on 
enhancers including looping. However, this result is contradictory to the studies from 
the Rosenfeld group which reported a role of eRNAs in mediating Cohesin 
recruitment and chromatin looping (Hah et al., 2013). Furthermore, in another 
system, CDK9 and BRD4 inhibition was shown to inhibit eRNA transcription from de 
novo enhancers, and enhancer transcription, and not the transcript itself is important 
for H3K4me2 deposition (Kaikkonen et al., 2013). Additionally, a recent report 
demonstrated that BRD4, in general, helps in the elongation of eRNA transcripts by 
allowing RNAPII to travel through the acetylated enhancer regions (Kanno et al., 
2014). This study also showed that eRNA transcription can be inhibited by JQ1 
without significantly affecting the association of BRD4 and P-TEFb around the TSS 
of BRD4-dependent genes such as Myc and Klf4. Altogether these studies suggest 
an important role of eRNA transcription which could be coordinated by BRD4 and 
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The estrogen receptor α (ERα) controls cell proliferation and tumorigenesis by 
recruiting various cofactors to estrogen response elements (EREs) to control gene 
transcription. A deeper understanding of these transcriptional mechanisms may 
uncover therapeutic targets for ERα-dependent cancers. We show that BRD4 
regulates ERα-induced gene expression by affecting elongation-associated 
phosphorylation of RNA polymerase II (RNAPII) and histone H2B 
monoubiquitination. Consistently, BRD4 activity is required for proliferation of ER+ 
breast and endometrial cancer cells and uterine growth in mice. Genome-wide 
studies revealed an enrichment of BRD4 on transcriptional start sites of active genes 
and a requirement of BRD4 for H2B monoubiquitination in the transcribed region of 
estrogen-responsive genes. Importantly, we demonstrate that BRD4 occupancy on 
distal EREs enriched for H3K27ac is required for recruitment and elongation of 
RNAPII on EREs and the production of ERα-dependent enhancer RNAs. These 
results uncover BRD4 as a central regulator of ERα function and potential 
therapeutic target. 
Introduction 
Estrogen receptor-positive (ER+) breast cancers represent a significant 
challenge to modern health care. ERα-dependent transcription in these cancers 
potentiates cell proliferation and malignancy. Estrogen (E2) binding leads to 
conformational changes within ERα that promote dimerization, binding to estrogen 
response elements (EREs), and subsequent cofactor recruitment (Deroo and 
Korach, 2006). Binding of ERα to EREs is promoted by the pioneer factor, Forkhead 
protein FOXA1 (HNF3α) (Carroll et al., 2005; Hurtado et al., 2011). ERα also 
functions along with Cohesin (Schmidt et al., 2010) to facilitate long-range 
chromosomal interactions between EREs (Fullwood et al., 2009). 
The regulation of transcriptional elongation plays an essential role in E2-
dependent gene transcription. This is largely regulated by the activity of the Positive 
Transcription Elongation Factor-b (P-TEFb) complex (Peterlin and Price, 2006). P-
TEFb promotes elongation in part by relieving negative regulation by phosphorylating 





(DRB)-sensitivity inducing factor (DSIF) complexes. Pausing of RNA polymerase II 
(RNAPII) by NELF just downstream of the transcriptional start site (TSS) is a critical 
determinant of ERα-dependent transcription (Aiyar et al., 2004). P-TEFb also 
phosphorylates Ser2 (p-Ser2) within the heptapeptide repeat of the RNAPII carboxy-
terminal domain (CTD). This in turn promotes elongation-associated histone 
modifications including histone H2B monoubiquitination (H2Bub1) (Karpiuk et al., 
2012; Pirngruber et al., 2009a), which is required for E2-dependent transcription 
(Bedi et al., 2015; Prenzel et al., 2011). Consistently, E2-dependent transcription 
was shown to be regulated at a post-RNAPII recruitment step involving increased 
RNAPII p-Ser2 by P-TEFb (Kininis et al., 2009). 
The Bromodomain-containing Protein 4 (BRD4) binds to acetylated histones 
at both enhancers and promoters and recruits P-TEFb to support lineage-specific 
gene transcription (Zippo et al., 2009; Zhang et al., 2012a). Importantly, inhibition of 
BRD4 by pan-bromodomain and extraterminal domain (BET) inhibitors such as JQ1 
(Filippakopoulos et al., 2010), PFI-1 (Picaud et al., 2013a), and IBET revealed the 
involvement of BRD4 in various cancers in animal models (Herrmann et al., 2012; 
Lockwood et al., 2012; Ott et al., 2012; Zhang et al., 2012b; Zuber et al., 2011). 
Moreover, a BRD4-dependent gene expression signature was reported to be a 
positive predictor of breast cancer survival (Crawford et al., 2008) and has been 
implicated as an inherent susceptibility gene for metastasis in breast cancers 
(Alsarraj et al., 2011). 
Recent findings describe a role for enhancer RNA (eRNA) production from 
ERα-bound enhancers during E2-regulated transcription (Hah et al., 2013; Li et al., 
2013). eRNAs are noncoding RNAs that promote transcription by an unknown 
mechanism (Kim et al., 2010). Interestingly, cyclin-dependent kinase 9 (CDK9) is 
required for E2-regulated eRNA synthesis (Hah et al., 2013). 
In this study, we investigated a role for BRD4 as a transcriptional cofactor of 
ERα-induced transcription by regulating transcriptional elongation and revealed its 
recruitment both to gene promoters as well as FOXA1-ERα-bound enhancers in ER+ 
breast cancer cells. Moreover, we demonstrate that distal EREs that produce eRNAs 






BRD4 regulates E2-induced transcriptional activity in ER+ cancers 
To analyze the importance of BRD4 in ERα-dependent gene regulation, we 
performed mRNA sequencing (mRNA-seq) analyses in ER+ breast cancer cells 
following E2 stimulation in cells depleted for BRD4 or treated with the BRD4 inhibitor, 
JQ1 (Figure 2.I.S1A). Heatmap analysis shows a nearly global decrease of E2-
stimulated gene expression following BRD4 depletion and inhibition (Figure 2.I.1A 
and 2.I.S1C), whereas the effects of BRD4 perturbation in this time frame were less 
apparent for E2-downregulated genes (Figure 2.I.S1D). The inhibition of E2-induced 
transcription by BRD4 perturbation was further verified for representative E2-
upregulated genes (Figure 2.I.S1B).  
 
Figure 2.I.1A. BRD4 perturbation impairs E2-induced gene expression. Heatmap made with log2-
fold changes from mRNA-seq of MCF7 cells. E2 denotes siCont and E2-treated samples relative to 





relative to siCont with E2 induction. JQ1+E2 denotes siCont, JQ1, and E2-treated samples relative to 
siCont with E2 induction. Only E2-upregulated genes R1.5-fold are shown. Adjusted p value is ≤ 0.05. 
 
Figure 2.I.1B. BRD4 perturbation impairs E2-induced gene expression. GSEA of mRNA 
expression data from RNA-seq. The table shows the enrichment score for the topmost estrogen-
related pathways in each condition. Nominal p value is ≤ 0.05, FDR ≤ 25%. 
 
Figure 2.I.1C,D. BRD4 perturbation impairs E2-induced gene expression, RNA polymerase Ser2 
phosphorylation, and H2Bub1. Western blot analyses with specific antibodies on whole MCF7 
protein extracts after transfection with negative control (-) or siBRD4 with 6 or 24 hr of E2 induction 
(C) or DMSO (-) or JQ1 and/or E2 induction for 24 hr (D). Relative quantified values of H2Bub1 
normalized with H2B and ERα with HSC70 are indicated under the respective blots. 
Strikingly, in addition to the known targets of BRD4 such as cell proliferation-
specific and tumor necrosis factor-nuclear factor κB target genes (Mochizuki et al., 





E2- and ERα-related pathways as being significantly enriched following BRD4 
knockdown or inhibition under vehicle (Veh) as well as E2-treated conditions (Figure 
2.I.1B, 2.I.S1E, and 2.I.S1F). Similar effects were also seen in the ER+ Ishikawa 
endometrial cancer cell line (Figure 2.I.S1G), whereas BRD4 depletion had little or 
no effect on transforming growth factor β1 (TGF-β1)-induced gene expression 
(Figure 2.I.S1H). Together, these findings indicate a specific and central role for 
BRD4 in regulating E2-induced transcription in ER+ cancers. 
BRD4 regulates RNAPII phosphorylation and H2Bub1 
Given the importance of BRD4 in controlling RNAPII elongation (Liu et al., 
2013; Patel et al., 2013), and the established roles for RNAPII p-Ser2 (Kininis et al., 
2009) and H2Bub1 (Prenzel et al., 2011) in E2-induced gene transcription, we 
examined whether BRD4 depletion or inhibition affects RNAPII p-Ser2 or H2Bub1. 
Interestingly, both RNAPII p-Ser2 and H2Bub1 substantially increased upon E2 
treatment, and depletion or inhibition of BRD4 decreased their levels under basal as 
well as E2-induced conditions (Figure 2.I.1C, 2.I.1D, and 2.I.S1J). Similar effects 
were also observed in Ishikawa and H1299 cells upon BRD4 depletion (Figure 
2.I.S1I). 
BRD4 regulates ERα-dependent cell proliferation and uterine growth 
In order to investigate the physiological function of BRD4 in controlling ERα 
activity, we examined cell proliferation after knockdown or inhibition of BRD4 in both 
MCF7 and Ishikawa cells. Notably, consistent with gene expression results (Figure 
2.I.1A, 2.I.1B, and 2.I.S1B–S1F), BRD4 perturbation decreased cell proliferation in a 
manner similar to the pure anti estrogen ICI182780 both in the presence and 
absence of E2 (Figure 2.I.2A, 2.I.S2A, and 2.I.S2B). 
Decreased uterine weight is a hallmark of diminished estrogen signaling in 
vivo. Consistent with in vitro experiments, JQ1-injected mice demonstrated a 
substantial decrease in uterine growth (Figure 2.I.2B) and uterine wet weight (Figure 
2.I.2C), without significant changes in total body weight (Figure 2.I.S2C). Gene 
expression analyses confirmed decreased expression of E2-dependent genes in 
uteri from JQ1-injected mice (Figure 2.I.2D), confirming a central role for BRD4 in 






Figure 2.I.2. Inhibition and knockdown of BRD4 affect proliferation and uterine growth. (A) Cell 
proliferation assays in MCF7 cells upon E2 as well as basal conditions under negative siCont, 
siBRD4, JQ1, and ICI182780 treatment. (B–D) Three-week-old mice injected with Veh (Cont [control]) 
and JQ1 for 3 weeks were dissected, and uteri were analyzed for their size (B) and wet weight (wt.) 
(C). ***p ≤ 0.001. Data are represented as mean ± SD (n = 8). (D) Single-gene expression analyses of 
E2-induced genes (Ran, Mad2l1, and Il1b) after Veh (cont) or JQ1-injected mouse uteri. *p ≤ 0.05; **p 
≤ 0.01. The data are represented as median ± SD (n = 4). Rel. mRNA exp., relative mRNA 
expression. 
BRD4 occupancy is associated with an active epigenetic context and 
transcription 
To gain mechanistic insight into the function of BRD4 and H2Bub1 in ERα-





(ChIP) and sequencing (ChIP-seq) analyses. Consistent with its role in E2-induced 
gene transcription, genome-wide profiling and single-gene analyses revealed 
increased BRD4 occupancy slightly downstream of the TSS and continuing into the 
transcribed region of E2-induced genes (Figure 2.I.3A, 2.I.3B, and 2.I.S3A–S3G). 
This occupancy is decreased upon JQ1 treatment (Figure 2.I.S3B). Conversely, E2 
reduced BRD4 recruitment on E2-repressed genes (Figure 2.I.S3D and 2.I.S3F). 
Consistent with a previous study by (Minsky et al., 2008)), H2Bub1 preferentially 
occupied gene bodies (Figure 2.I.3C, 2.I.3D, and 2.I.S3H–S3L). Notably, E2 
treatment increased H2Bub1 levels on E2-stimulated genes significantly, and this 
effect was reduced by JQ1 treatment (Figure 2.I.3C, 2.I.S3I, and 2.I.S3K–S3M). 
Interestingly, the effect of JQ1 on H2Bub1 occupancy was most pronounced on 
genes exhibiting de novo RNAPII recruitment, such as GREB1 and TFF1, but less 
on RNAPII-recruited and -preloaded and -constitutively bound genes like XBP1 
(Figure 2.I.S3K and 2.I.S3N). 
 
Figure 2.I.3A,B. BRD4 occupies promoters and correlates with active transcription. (A) 
Genomic binding profiles of BRD4 on E2-induced genes (GREB1 and TFF1) and a housekeeping 
gene (ACTB). Red indicates E2-treated and green indicates Veh-treated conditions. (B) Aggregate 
plots showing genomic binding profiles of BRD4 on E2-upregulated gene-specific TSS upon Veh and 
E2-treated conditions. x axis shows the distance from the TSS of E2-upregulated genes in kilobase 
pairs. y axis shows the average BRD4 signal of the reads normalized per hundred million base pairs. 






Figure 2.I.3C,D. BRD4 occupies promoters and correlates with active transcription. (C) 
Aggregate plots showing genomic profiles of H2Bub1 on E2-upregulated genes upon Veh, JQ1, as 
well as Veh (JQ1 Veh), E2, and JQ1 as well as E2 (JQ1 E2)-treated conditions. Weighted averages 
for each E2-upregulated gene, 1.5–2.5 kb downstream of each TSS, were used to calculate the p 
values using ANOVA with multiple-regression model. ***p ≤ 0.001. (D) Genomic profiles of H2Bub1 on 
GREB1, TFF1, and ACTB. Red indicates E2-treated and green indicates JQ1 as well as E2 (JQ1 E2)-
treated conditions. 
 
Figure 2.I.3E. BRD4 occupies promoters and correlates with active transcription. Correlation 
plot on E2-regulated gene-specific TSS +3 kb showing the association of BRD4, H3K27ac, H3K4me3, 
nascent RNA transcription (GRO-seq), RNAPII, H2Bub1, and DNase I-hypersensitivity sites (DNase-






 Figure 2.I.3F. BRD4 occupies promoters and correlates with active transcription. Aggregate 
plot analyses of BRD4, H3K27ac, RNAPII, and H2Bub1 on GRO-seq-based groups (high, medium, 
low, and null), at specific TSSs on E2-regulated genes. ‘‘High’’ group corresponds to E2-upregulated 
TSS having a weighted average of GRO-seq signal from E2-treated MCF7 cells >0.3, ‘‘medium’’ 
>0.15 <0.3, ‘‘low’’ >0 <0.15, and ‘‘null’’ with no value of average. A class of H3K27me3-positive 
summits was examined as a negative control of active transcription. 
Correlation and aggregate plots confirmed an association of BRD4 and active 
transcription on E2-induced TSSs (Figure 2.I.3E, 2.I.3F, and 2.I.S3O–S3R). 
Moreover, BRD4 occupancy positively correlated with histone marks H3K27ac and 
H3K4me3, which are hallmarks of active transcription, as well as RNAPII, H2Bub1, 
and DHSs (DNase I-hypersensitivity sites), but not with H3K27me3 (Figure 2.I.3E 
and 2.I.S3O). Similarly, H2Bub1 also correlated with transcription, H3K4me3, BRD4, 
H3K27ac, and RNAPII (Figure 2.I.3E and 2.I.S3O). Grouping of TSSs according to 
the level of nascent RNA expressed (high, medium, low, and null) and aggregate plot 
and heatmap analyses revealed a clear association of BRD4, H3K27ac, H3K4me3, 
RNAPII, and H2Bub1 occupancy as well as DHSs and gene transcription (Figure 





BRD4 functions downstream of ERα, H3K27ac, and Cohesin 
Because BRD4 inhibition prevents E2-dependent gene induction without 
appreciably affecting ERα protein levels (Figure 2.I.1D and 2.I.S4A), we also 
examined the effects of JQ1 treatment on the recruitment of ERα and the Cohesin 
subunit RAD21. Single-gene analyses of ERα binding suggested that ERα binding is 
not affected at specific EREs after BRD4 inhibition (Figure 2.I.4A and 2.I.S4B). 
Consistent with a recent report describing an effect of BRD4 inhibition on androgen 
receptor (AR) recruitment (Asangani et al., 2014), genome-wide analyses confirmed 
that JQ1 treatment decreases ERα binding at most EREs (Figure 2.I.4B, 2.I.S4D, 
and 2.I.S4E). However, these effects are only partial, and substantial levels of ERα 
are still bound to EREs after JQ1 treatment (Figure 2.I.S4F). Consistent with the 
recent studies that BRD4 does not promote chromosomal looping between 
enhancers and promoters (Liu et al., 2013), RAD21 binding to three different EREs 
known to serve as hubs for ERα-dependent looping (Fullwood et al., 2009) was 
unaffected by JQ1 treatment (Figure 2.I.S4C). Interestingly, whereas BRD4 binding 
correlated with H3K27ac (Figure 2.I.3E) (Zhang et al., 2012a), BRD4 inhibition did 
not influence the E2-induced H3K27ac on individual E2-regulated enhancers and 
promoters (Figure 2.I.4C and 2.I.S4H). These results suggest that BRD4 is recruited 
to E2-regulated genes subsequent to ERα binding, histone acetylation, and Cohesin 
recruitment. 
BRD4 occupies enhancers and regulates eRNA synthesis by affecting RNAPII 
recruitment and elongation 
BRD4 was recently shown to occupy and regulate enhancer function (Liu et 
al., 2013; Zhang et al., 2012a). Thus, we examined BRD4 occupancy at distal EREs 
and observed that BRD4 is recruited to distal EREs in an E2-dependent manner and 
correlated with H3K27ac, ERα, FOXA1, RNAPII, and DHS (Figure 2.I.4D, 2.I.4E, 
2.I.4H, 2.I.S4G and 2.I.S4I–S4L). Surprisingly, nascent RNA transcription on 
enhancers correlated with BRD4 occupancy to a greater extent than the other 
investigated profiles (Figure 2.I.4E–4H). RNAPII occupancy is also well associated 
with BRD4 on enhancers (Figure 2.I.4E). Interestingly, high eRNA-producing EREs 
exhibited high E2-induced RNAPII recruitment that extended to more than 5 kb 





between RNAPII recruitment and elongation at eRNA-producing enhancers (Figure 
2.I.4I and 2.I.S4N). ChIP analyses confirmed that E2-induced RNAPII recruitment 
and elongation at the GREB1 ERE are decreased by JQ1 treatment (Figure 2.I.4J, 
2.I.4K, and 2.I.S4O). Altogether, these studies suggest that in addition to its role in 
transcriptional elongation, BRD4 affects both recruitment and elongation of RNAPII 
on ERα-dependent enhancers. 
 
Figure 2.I.4A,B. BRD4 binds to ER+ enhancers after ERα recruitment and H3K27ac. (A) ChIP-
quantitative PCR (ChIP-qPCR) analyses of ERα occupancy on GREB1 ERE after DMSO or JQ1 
treatment with Veh or E2 induction. ***p ≤ 0.001. Data are represented as mean ± SD (n = 3). Dotted 
line indicates background. (B) Aggregate plot showing genomic binding profiles of ERα on distal 
EREs upon E2-treated and JQ1 as well as E2 (JQ1 E2)-treated conditions. x axis shows the distance 
from the center of ERE in kilobase pairs. y axis shows the average ERα signal of the reads 
normalized per hundred million base pairs. Weighted averages for each ERE ±100 bp were used to 
calculate the p values using ANOVA with repeated measures with ANOVA with multiple-regression 
model. p value is mentioned in the plot. 
 
Figure 2.I.4C. BRD4 binds to ER+ enhancers after ERα recruitment and H3K27ac. ChIP-qPCR 





overlapping region and GREB1 TSS. The data are represented as mean ± SD (n = 3). **p ≤ 0.01; n.s., 
not significant. 
 
Figure 2.I.4D. BRD4 binds to ER+ enhancers after ERα recruitment. Aggregate plot showing 
genomic binding profiles of BRD4 on distal EREs upon Veh and E2-treated conditions.  
 
Figure 2.I.4E. BRD4 binds to ER+ enhancers after ERα recruitment and H3K27ac and regulates 
eRNA synthesis. Correlation plot on distal EREs ±1.5 kb showing the association of BRD4, 






Figure 2.I.4F. BRD4 binds to ER+ enhancers after ERα recruitment and H3K27ac and regulates 
eRNA synthesis. Aggregate plot analyses of BRD4, H3K27ac, ERα, FOXA1, and RNAPII occupancy 
on GRO-seq-based classified distal EREs. ‘‘High’’ group corresponds to distal EREs having a 







Figure 2.I.4G. BRD4 binds to ER+ enhancers after ERα recruitment and H3K27ac and regulates 
eRNA synthesis. Heatmap profiles of BRD4, H3K27ac, ERα, FOXA1, nascent RNA transcription 
(GRO-seq), and RNAPII occupancy on ±5 kb of distal EREs aligned from high to null GRO-seq 







Figure 2.I.4H. BRD4 binds to ER+ enhancers after ERα recruitment and H3K27ac and regulates 
eRNA synthesis. Binding profiles of BRD4, H3K27ac, ERα, GRO-seq, and RNAPII on GREB1 
proximal and distal EREs and promoter. BRD4 with red peaks indicates E2-treated and green 
indicates Veh-treated conditions. RNAPII with blue peaks indicates E2-treated and light green 
indicates Veh-treated conditions.  
 
Figure 2.I.4I,J,K. BRD4 binds to ER+ enhancers after ERα recruitment and H3K27ac and 
regulates eRNA synthesis. (I) Aggregate plot showing genomic binding profiles of RNAPII on distal 
EREs that produce high eRNA (GRO-seq group ‘‘high’’) upon Veh and E2-treated conditions. (J and 
K) ChIP-qPCR analyses of RNAPII (J) and RNAPII-PSer2 (K) occupancy on GREB1 ERE after 
DMSO or JQ1 treatment with Veh or E2 induction. *p ≤ 0.05. Data are represented as mean ± SD (n = 






Figure 2.I.4L. BRD4 binds to ER+ enhancers after ERα recruitment and H3K27ac and regulates 
eRNA synthesis. (L) eRNA-qPCR results showing E2-induced eRNA (eGREB1 and eXBP1) upon 
negative siCont, siBRD4, or JQ1 treatment with Veh or E2 induction. Relative RNA levels are shown 
as ‘‘Rel. RNA levels.’’ Data are represented as mean ± SD (n = 3). 
Importantly, BRD4 depletion or inhibition significantly decreased eRNA 
synthesis from E2-regulated enhancers (Figure 2.I.4L). This suggests that in addition 
to its reported cis-regulatory function, BRD4 may stimulate E2-induced mRNA 
transcription by promoting eRNA production at distal EREs. 
Discussion 
The hierarchical epigenetic regulation of transcriptional activation involves an 
intricate network of interactions among various transcription factors, histone-
modifying enzymes, epigenetic readers, and the transcriptional machinery. In this 
study, we investigated the function of the epigenetic reader BRD4 in controlling E2-
regulated gene transcription. Our findings support a model in which ERα recruits 
histone acetyltransferases to a subset of EREs enriched for FOXA1 to facilitate 
histone acetylation and subsequent recruitment of BRD4 and RNAPII in order to 
promote eRNA synthesis (Figure 3.1). 
To date, most studies have focused largely on the role of BRD4 as a promoter 
proximal regulator of mRNA synthesis by increasing P-TEFb recruitment. Consistent 
with a direct function of BRD4 on target gene transcription, we show that BRD4 
promotes elongation-associated phosphorylation of RNAPII and monoubiquitination 
of histone H2B. These results are consistent with an established essential role for 
H2Bub1 in E2-stimulated transcription (Prenzel et al., 2011) and the dependence of 
H2Bub1 upon CDK9 (Pirngruber et al., 2009a). In addition to a cis-regulatory 





consistent with a previous finding that CDK9 is recruited by BRD4 to distal intergenic 
enhancer regions marked by H3K27ac (Lovén et al., 2013). Notably, we show that 
BRD4 co-occupies eRNA-producing enhancers with ERα, FOXA1, and H3K27ac, 
regulates RNAPII recruitment on ERα-bound enhancers, and is required for the 
production of eRNA transcripts. These findings support a role for BRD4 in hormone-
dependent cancers (Asangani et al., 2014) and suggest a model in which eRNA 
synthesis requires a coordinated epigenetic hierarchy that culminates in the 
recruitment of BRD4 and RNAPII and subsequent transcription from a select subset 
of distal EREs. 
The importance of BRD4 in E2-regulated transcription is consistent with 
previously identified interactions between BRD4 and ERα (Wu et al., 2013) as well 
as ERα and CDK9 (Sharp et al., 2006) or cyclin T1 (Wittmann et al., 2005). 
Furthermore, the 7SK component HEXIM1, which suppresses P-TEFb activity, 
negatively regulates ERα transcriptional activity (Wittmann et al., 2005), and its 
overexpression induces tamoxifen resistance (Ketchart et al., 2011). Importantly, 
recent data showed that CDK9 activity is required for the production of eRNAs at 
distal EREs (Hah et al., 2013) and the role of eRNA and MED1 in regulating AR-
dependent transcription and looping (Hsieh et al., 2014). Thus, consistent with our 
model, P-TEFb and BRD4 likely promote ERα-mediated transcriptional activation at 
least in part by promoting eRNA transcription. 
ERα functions together with Cohesin to nucleate chromosomal looping that 
promotes E2-regulated transcription (Fullwood et al., 2009; Schmidt et al., 2010). 
Our previous study showed that proteasomal inhibition specifically decreases ERα-
regulated transcription by decreasing H2Bub1 and transcriptional elongation without 
affecting long-range chromosomal interactions (Prenzel et al., 2011). Consistently, 
CDK9 inhibition decreased ERα-dependent gene expression without affecting ERα 
occupancy, coactivator recruitment, or chromosomal looping (Hah et al., 2013). 
Similarly, our data show that BRD4 inhibition had little or no effect on ERα 
recruitment, E2-stimulated H3K27 acetylation, or Cohesin recruitment, indicating that 
BRD4 functions along with CDK9 downstream of early enhancer activation events 





Numerous recent studies have shown a substantial therapeutic potential for 
BRD4 inhibition in various malignant diseases (Zuber et al., 2011; Herrmann et al., 
2012; Lockwood et al., 2012; Asangani et al., 2014; Ott et al., 2012; Filippakopoulos 
et al., 2010; Zhang et al., 2012b), leading to the testing of several BET domain 
inhibitors in a clinical setting for certain types of tumors (Filippakopoulos and Knapp, 
2014). However, the utility of BET inhibitors in ERα+ breast cancer has not been 
investigated. Here, we describe a function of BRD4 in specifically controlling E2-
dependent gene transcription in ERα+ normal and malignant cells in vitro and in vivo. 
We provide mechanistic insight to support a previously unknown mechanism by 
which BRD4 controls distal enhancer activity and target gene expression by 
promoting eRNA synthesis. We hypothesize that this BRD4-dependent mechanism 
likely controls other enhancer-driven transcriptional programs directing processes 
such as lineage specification during cell differentiation and development. Moreover, 
these findings may potentially serve to provide a mechanistic-based approach to the 
treatment of ERα+ breast cancer. 
Experimental Procedures 
Cell Culture, Transfections, Inhibitors, and siRNAs 
MCF7 cells were provided by K. Pantel (University Medical Center, Hamburg-
Eppendorf), Ishikawa from T. Spelsberg (Mayo Clinic, Rochester), and H1299 from 
M. Dobbelstein (University Medical Center, Göttingen). They were grown in phenol 
red-free high-glucose Dulbecco’s modified Eagle’s media (DMEMs; Invitrogen) 
supplemented with 10% bovine growth serum (Thermo Scientific), 1% sodium 
pyruvate, and 1% penicillin/streptomycin (Sigma-Aldrich). Forward and reverse 
transfections were performed using DharmaFECT 1 (Thermo Scientific) for small 
interfering RNAs (siRNAs) according to the manufacturer’s instructions. Nontargeting 
(negative control) and BRD4 siRNAs (siBRD4s) were obtained from Dharmacon 
(Thermo Scientific). BRD4 SmartPool siRNA (Dharmacon) contained the sequences 
5′-AGCUGAACCUCCCUGAUUA-3′, 5′-UGAGAAAUCUGCCAGUAAU-3′, 5′-
UAAAUGAGCUACCCACAGA-3′, and 5′-GAACCUCCCUGAUUACUAU-3′. JQ1 (150 
nM) was used to pretreat the cells 30 min before E2 induction. 17 β-estradiol and 





ethanol was used as Veh. ICI182780 (Fulvestrant) was used at the concentration of 
1 μM. TGF-β1 (2 ng/ml) treatment was done on H1299 cells for 90 min. 
E2-induction experiments were carried out by changing the media to DMEM 
supplemented with 5% charcoal-dextran-treated fetal bovine serum (CSS; Sigma-
Aldrich), 1% sodium pyruvate, and 1% penicillin/streptomycin after 24 hr of cell 
growth. After 48 hr of hormone deprivation, they were treated with 17 β-estradiol for 
2, 6, or 24 hr. Ethinyl estradiol was used for proliferation assays in Ishikawa cells. 
TGF-β1 treatment in H1299 cells was given after growing the cells in serum-free 
media for 48 hr. 
MCF-7 cells were harvested for RNA upon Veh or E2 treatment, and negative 
control siRNA (siCont), siBRD4, or JQ1 transfection. JQ1-treated cells were also 
transfected with negative siCont. Ishikawa and H1299 cells were harvested for RNA 
under Veh or E2 treatment, or TGF-β1 treatment and negative siCont or siBRD4. 
RNA-Seq 
RNA integrity was checked using Bioanalyzer 2100 (Agilent Technologies). A 
total of 500 ng of total RNA was used for preparing libraries using TruSeq RNA 
Sample Preparation Kit (Illumina), and the size range was checked to be 280 bp 
using Bioanalyzer. These samples were amplified and sequenced by using cBot and 
HiSeq 2000 from Illumina, respectively, for 51 bp single-ended tags with single 
indexing. Images from the sequencing results were processed using BaseCaller to 
bcl files function in Illumina software. These were demultiplexed to fastq files using 
CASAVA 1.8.2 and mapped to the human reference transcriptome (UCSC HG19) 
using Bowtie 2 (version 2.1.0) (Langmead and Salzberg, 2012). Read counts for 
each sample and each gene were aggregated using a custom Ruby script. DESeq 
(version 1.14.0) was used for measuring differential expression (Anders and Huber, 
2010). 
Gene Set Enrichment Analysis 
Pathway enrichment scores were calculated by GSEA (Subramanian et al., 
2005). The gene expression data from RNA sequencing (RNA-seq) analyses are 





expression data set was compared with C2-curated gene sets that include published 
gene sets from pathways of chemical and genetic perturbations, canonical pathways, 
BIOCARTA, Reactome, and KEGG. WILLIAMS_ESR1_TARGETS_UP (Williams et 
al., 2008), FRASOR_RESPONSE_TO_ESTRADIOL_UP (Frasor et al., 2004), 
MASSERWEH_RESPONSE_TO_ESTRADIOL (Massarweh et al., 2008), 
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP (Bhat-Nakshatri et al., 2008), 
DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP (Dutertre et al., 2010), 
PID_HNF3A_PATHWAY (Schaefer et al., 2009), STEIN_ESR1_TARGETS (Stein et 
al., 2008), MASSERWEH_TAMOXIFEN_RESISTANCE_DN (Massarweh et al., 
2008), and CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4 (Creighton et 
al., 2008) are shown as E2-related topmost enriched pathways under BRD4 
perturbation. 
ChIP 
ChIP and subsequent real-time PCR analyses with specific primers (Table 
S3) were performed as before (Bedi et al., 2015; Prenzel et al., 2011) for BRD4, 
ERα, RAD21, H3K27ac, and H2Bub1. ChIP-seq was performed for BRD4, ERα, and 
H2Bub1. BRD4 ChIP was performed by crosslinking the chromatin for 20 min in 1% 
formaldehyde. Other antibodies and their dilutions were used as described before 
(Table S1) (Bedi et al., 2015; Prenzel et al., 2011). 
ChIP-Seq and Bioinformatic Analyses 
Prior to library preparation, immunoprecipitated DNA was sonicated an 
additional time to ensure fragment sizes less than 200 bp. Libraries were prepared 
using the NEBNext Ultra DNA library preparation kit according to the manufacturer’s 
instructions. Size range was verified to be 280–300 bp using Bioanalyzer 2100. A 
total of 50 cycles were used for amplification in cBot, and 101 bp single-ended tags 
for BRD4 and 51 bp single-ended tags for other ChIP samples were sequenced with 
single indexing using Illumina HiSeq 2500. Raw data for FOXA1, H3K4me3, 
H3K27me3 (Joseph et al., 2010), H3K27ac (Theodorou et al., 2013), RNAPII 
(Welboren et al., 2009), DNase sequencing (DNase-seq) (Thurman et al., 2012), and 
global run-on (GRO) sequencing (GRO-seq) (Hah et al., 2013) were downloaded 





Table S4. The reads were mapped to the human reference genome (UCSC HG19) 
using Bowtie (version 1.0.0) (Langmead et al., 2009). Peak calling was done by 
Model-based Analysis of ChIP-Seq (version 1.4.2) (Zhang et al., 2008). Coverage 
was determined by normalizing the total number of mapped reads per hundred 
million. For plotting correlation, aggregation, ChIP enrichment signals over specific 
genomic features, and heatmaps, Cistrome (Liu et al., 2011) based on the Galaxy 
framework was used. Data were visualized in Integrative Genomics Viewer (version 
2.3.14) (Thorvaldsdóttir et al., 2013). Common TSS and gene body coordinates were 
obtained from UCSC Table Browser (Karolchik et al., 2004). Distal EREs were 
defined as ERα binding sites not within gene bodies or regions 5 kb upstream or 
downstream thereof. Regions covering the TSS and 3 kb downstream of it were 
used for TSS-oriented correlation plots and 1.5 kb up- and downstream to distal 
EREs for distal ERE-oriented correlation plots. Average signals of GRO-seq data 
with E2 treatment were calculated using assign weighted average function in 
Cistrome surrounding TSS (plus 3 kb) or ERE (±1.5 kb). These values were used to 
group the TSS or ERE coordinates as high, medium, low, and null. For distal EREs, 
the “high” group corresponds to distal EREs having a weighted average greater than 
0.45, “medium” has >0.25 <0.45, “low” has >0 ≤0.25, and “null” has a zero (0) 
average. For TSSs, the “high” group corresponds to distal EREs having a weighted 
average greater than 0.3, “medium” has ≥0.15 <0.3, “low” has >0 <0.15, “null” has a 
zero (0) average. The range for these groups was chosen according to the similar 
number of TSSs or EREs in each group and adequate GRO-seq enrichment signal 
defined for each group. H3K27me3-positive coordinates were obtained using the 
summits of H3K27me3 ChIP-seq signal (Joseph et al., 2010). For measuring 
statistical significance of aggregate plots, weighted averages for each E2-
upregulated gene, 1.5–2.5 kb downstream of each TSS or distal ERE ±100 bp, were 
used to compute a multiple-linear regression model. Within the multiple-linear 
regression model, the weighted average within a 1 kb window was used as a 
dependent variable, given the independent variables of condition and gene. The 
condition variable was tested for significant impact using an ANOVA. Groups of E2-
upregulated genes based on RNAPII occupancy (RNAPII recruited de novo, RNAPII 
preloaded and recruited, and RNAPII constitutively bound) were kindly provided by 
W. Lee Kraus. E2 up- (≥1.5-fold), down- (≤0.8-fold), and nonregulated genes were 





In Vivo Experiments in JQ1-Injected Mice 
Three-week-old C57BL/6 female mice were injected intraperitoneally with JQ1 
(50 mg/kg) or Veh (5% DMSO in 5% dextrose) for 3 weeks (n = 8 for each group). 
Mice were sacrificed via CO2 inhalation, and uteri were collected to examine 
differences in their size and weight. Difference in the uterine weight between control 
(DMSO) and JQ1-injected mice was calculated by normalizing the uterine wet weight 
(in milligrams) with respect to body weight (in grams). Uteri (n = 4 for each group) 
were homogenized using beads by FastPrep FP120 homogenizer (Thermo 
Scientific), and RNA was isolated using TRIzol (QIAGEN) according to 
manufacturer’s instructions. Normalization was done using starting quantity values of 
glyceraldehyde 3-phosphate dehydrogenase. Relative mRNA expression analyses 
were done as mentioned before (but not normalized for control conditions) using 
gene-specific primers for the E2-dependent and cell-cycle-related genes Ran and 
Mad2l1 (Suzuki et al., 2007) and the reproduction-related gene Il1b (Weihua et al., 
2000). Primers are listed in Table S2. Statistical significance was analyzed using 
Student’s t test. All animal studies were performed in compliance with the 
requirements of the German Animal Welfare Act. 
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2.1.1. Supplemental Information 
2.1.1.1. Supplemental tables 
Supplemental Table S1 related to Experimental procedures 
Antibodies used for Western Blot and ChIP/ChIP-seq 
 
Target Protein Clone Cat.No. ChIP WB Source 
Beta-Actin I-19 sc1616 - 1:5000 Santa Cruz 
ERα HC-20 sc-543 1 µg 1:1,000 Santa Cruz 
H2B  ab1790 - 1:15,000 Abcam 
H2Bub1 D11 5546 1.5 µL - Cell signaling 
H2Bub1 7B4  - 1:10 Hybridoma (Prenzel et al., 2011) 
H3K27ac  pAb-196-050 1 µg - Diagenode 
RAD21  ab992 1 µg - Abcam 
HSC70 B-6 sc-7298 - 1:25,000 Santa Cruz 
RNAPII N-20 sc-899 1 µg  Santa Cruz 
RNAPII P-Ser2 3E10  - 1:10 Hybridoma (Prenzel et al., 2011) 
RNAPII P-Ser2  A300-654A 0.4 µg  Bethyl (Prenzel et al., 2012) 
BRD4  5716-1 - 1:5000 Epitomics 
BRD4(N-term)   4 µL - (Wu et al., 2006) 
 
Supplemental Table S2 related to Experimental procedures 
Primers used for qPCR in 5’ to 3’ orientation. Primers were designed using PRIMER BLAST in these studies. 
 
Gene  Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) Source 
GREB1  GTGGTAGCCGAGTGGACAAT ATTTGTTTCCAGCCCTCCTT (Prenzel et al., 2011) 
TFF1 CCCAGCACGGTGATTAGTCC GTCAATCTGTGTTGTGAGCCG This study 
BRD4 GCCGTCCACACTGCGTGAGC TCCCGGGGTGCCCCTTCTTT This study 
18SrRNA AACTGAGGCCATGATTAA GGAACTACGACGGTATCTGA (Bedi et al., 2015) 
DHFR ATGGTTGGTTCGCTAAACT TGAAGAGGTTGTGGTCATTC (Pirngruber et al., 2009b) 
TGF-α GCCTTCAAAACTCTGTCAAG CACATGTGGACTCAGACACC This study 
KLF10 TAGCAGCCAGTCAGCTTG AGTCTGCTGGAGAGAGGC This study 
SERPINE1 CTCTCTCTGCCCTCACCAAC GGTCATGTTGCCTTTCCAGT This study 
SMAD7 CCAACTGCAGACTGTCCAGA CAGGCTCCAGAAGAAGTTGG This study 
Ran ACTCTTCTGGAAGGATCCGC TCTTCTCAAACTCGCCCGTC This study 
Mad2l1 GTCCCAGAAAGCCATACAGGA TCAGCAGATCAAAGGAACAAGAA This study 
Il1b TGAAGAAGAGCCCATCCTCTG GGAGCCTGTAGTGCAGTTGT This study 
Gapdh GGCAAATTCAACGGCACAGT CCTTTTGGCTCCACCCTTCA This study 
eGREB1 GCTAACCATGCTGCAAATGA ACACAGTCAGGGCAAAGGAC (Li et al., 2013) 
eXBP1 TGTGAGCACTTGGCATCCAT ACAGGGCCTCATTCTCCTCT This study 
 
Supplemental Table S3 related to Experimental procedures 
Primers used in ChIP studies in 5’ to 3’ orientation. 
 
Gene  Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) Source 
GREB1 TSS  GCCAAATGGAAGAAGGACAG ACCACCTACCTCCAGTCACC  (Prenzel et al., 2011) 
GREB1 ERE GCTGACCTTGTGGTAGGCAC CAGGGGCTGACAACTGAAAT (Prenzel et al., 2011) 
GREB1 ERE (RNAPII 
PSer2) 
GCTAACCATGCTGCAAATGA ACACAGTCAGGGCAAAGGAC (Li et al., 2013) 
GREB1 H3K27ac+ ERE CACGTCCCCACCTCACTG TGTTCAGCTTCGGGACACC This study 
GREB1 TR CCCAAGCCTTCTCTGGGTTC AGCAGACGAGAAGTAGGGCT This study 
GREB1 3’ end GGGTGCCAAGTCGCTGCTGT CTGGATGGCAGAGGCGCCG (Prenzel et al., 2011) 
XBP1 TSS ATCCCCAGCTCTGGTCATCT GCCCAGGGCTCTTTTCTGTA This study 
XBP1 ERE TAGATTCCTTGCCCCGTGTC GAAAGAGGGGGTTGCCTGAG This study 
XBP1 H3K27ac+ ERE TGCTGTCCCTAAAGCAGTGG ATCCCAGCTCCTGATCCCAA This study 
TFF1 TSS  CCTGGATTAAGGTCAGGTTGGA TCTTGGCTGAGGGATCTGAGA (Prenzel et al., 2011) 
TFF1 ERE GACAGAGACGACATGTGGTGAGGTCA CACCCCGTGAGCCACTGTTGTC (Prenzel et al., 2011) 
TFF1 H3K27ac+ ERE GTGGTTCACTCCCCTGTGTC GAGGCATGGTACAGGAGAGC This study 
TFF1 TR CCACTCCCTAGAAGGACCCA GCTGGCAACCCATATTCCCT (Bedi et al., 2015) 







Supplemental Table S4 related to Experimental procedures 
Published genomic datasets  
 
Dataset NCBI accession numbers Source 
H3K27ac+E2 GSM986077 (Theodorou et al., 2013) 
GRO-seq+E2 GSM1067414, GSM1067415 (Hah et al., 2013) 
RNAPII+E2 GSM365930 (Welboren et al., 2009) 
DNase seq GSM816627 (Thurman et al., 2012) 
H3K4me3+E2 GSE23701 (Joseph et al., 2010) 
H3K27me3+E2 GSM588564 (Joseph et al., 2010) 
FOXA1+E2 GSM659787 (Joseph et al., 2010) 
 
2.1.1.2. Supplemental experimental procedures 
Western blot 
Protein lysates were prepared by incubating the cells with Radio 
Immunoprecipitation buffer (RIPA buffer - 1% (v/v) NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS in 1X PBS along with protease inhibitors: 1 mM 
Pefabloc, 1 ng/μL Aprotinin/Leupeptin, 10 mM β-glycerophosphate and 1 mM N-
ethylmaleimide) for 10 minutes. After brief sonication to release the chromatin 
associated proteins, 6X loading dye was added to the samples. These were boiled at 
95 ̊C for 5 -10 minutes and run in a SDS-PAGE. Proteins of interest were analyzed 
by Western blotting with antibodies and dilutions as described in Supplemental Table 
S1 (Bedi et al., 2015; Prenzel et al., 2011). Hsc70 and β-actin were used as loading 
control for cytoplasmic proteins and RNA polymerase II (total) and histone H2B for 
nuclear proteins. Quantification of proteins in Western Blot was done using ImageJ 
and H2Bub1 was normalized with H2B and ERα with HSC70.  
Quantification of gene expression and eRNA levels by quantitative real-time 
PCR 
RNA isolation and cDNA synthesis were performed as described before (Bedi 
et al., 2015; Prenzel et al., 2011). RNA isolation was done using TRIzol reagent 
(Qiagen) according to manufacturer's instructions. 1 μg of total RNA was reverse-
transcribed using random nonamer primers (Metabion and Sigma). Quantitative real 
time PCR (qPCR) reaction mix was prepared as follows: 75 mM Tris-HCl (pH 8.8), 
20 mM (NH4)2SO4, 0.01% (v/v) Tween-20, 3 mM MgCl2, 200 μM dNTPs, 0.5 
U/reaction Taq DNA Polymerase (Prime Tech, Minsk, Belarus), 0.25% (v/v) Triton X 
100, 1:80,000 SYBR Green I (Roche, Mannheim, Germany) and 300 mM Trehalose. 





μM gene-specific primers (listed in supplemental table S2) and 14 μL of qPCR 
reaction mix and made up for the final volume of 25 μL. PCR was done using C1000 
TM Thermal Cycler and CFX96 TM Optical Reaction Module (Bio-Rad, München, 
Germany) with 40 cycles of two-step amplification (95°C for 15 s and 60°C for 1 min) 
for each primer pair. A standard curve was determined from the dilutions of all cDNA 
samples for gene specific primers. This curve was used for the quantification of 
samples. Relative quantification was done by normalizing with starting quantity 
values of 18S ribosomal RNA in case of human cell-derived samples and Gapdh for 
mice samples. Expression levels of the samples were relatively determined with the 
vehicle-treated control samples and this relative mRNA expression is denoted as 
“Rel. mRNA exp.”. eRNA levels were tested by eRNA-specific primers (supplemental 
table S2) using qPCR and relative eRNA levels were calculated as mentioned above 
and denoted as “Rel. RNA levels”. Statistical significance was analyzed using 
ANOVA-single factor test. 
Cell proliferation assays 
For cell counting based proliferation assays, 10,000 MCF7cells were plated in 
normal growth medium which was replaced by hormone-deprived medium after 8 
hours. In case of siRNAs, reverse transfection was done. Cells were treated with 17-
β-estradiol, and or with siRNAs or inhibitors for 3, 5 and 7 days. Transfection was 
repeated after 72 hours in order to sustain the knockdown efficiency. The counting 
was performed using Neubauer’s chamber. For statistical significance, one way 
ANOVA was performed with Tukey HSD based multiple comparisons using SPSS 
package and p-values were calculated. 
 For Crystal violet based proliferation assays, 20,000 Ishikawa cells were 
plated in normal growth medium which was replaced by hormone-deprived medium 
after 8 hours. In case of siRNAs, reverse transfection was done. Cells were treated 
with ethinyl estradiol, and or with siRNAs or inhibitors for 7-9 days.  Transfection was 
repeated after 72 hours in order to sustain the knockdown efficiency. On confluency, 
colonies were fixed with 4 % paraformaldehyde for 5 minutes before staining with 0.1 
% crystal violet solution for 1 hour. Percentage of intensity covered by the cells after 
7-9 days of growth was quantified using ImageJ with a plugin ColonyArea (Guzmán 





Chromatin Immunoprecipitation (ChIP) 
 ChIP assays were performed as follows: Culture medium was removed from 
the cells and crosslinking of chromatin was performed by adding 1% formaldehyde 
(in PBS) for 10 minutes (20 minutes for BRD4 ChIP) at room temperature.  
Formaldehyde was quenched by adding 125 mM glycine at final concentration for 5 
minutes. After crosslinking, cells were washed with ice-cold PBS twice and then ice 
cold nuclear preparation buffer (150 mM NaCl, 20 mM EDTA (pH 8.0), 50 mM Tris 
(pH 7.5), 0.5% (v/v) NP-40, 1% (v/v) Triton X 100 and 20 mM Sodium Fluoride with 
protease inhibitors: 10 μM indole acetamide, 1mM nickel chloride, 1 mM Pefabloc, 1 
ng/μL aprotinin/leupeptin, 10 mM β-glycerophosphate and 1 mM N-ethylmaleimide) 
was added and the cells were scraped. The harvested cells were centrifuged and the 
nuclear pellet obtained was resuspended in 300 μL of sonication buffer-I (50 mM 
Tris-HCl (pH 8.0), 10 mM EDTA (pH 8.0), 1% SDS, with protease inhibitors 
mentioned above), incubated at 4 ̊C on a rotating wheel for 15 minutes and 
suspended in an equal volume of sonication buffer-II (150 mM NaCl, 20 mM EDTA 
(pH 8.0), 50 mM Tris-HCl (pH 8.0), 1% (v/v) NP-40, 20 mM Sodium Fluoride, with 
protease inhibitors). Sonication was done around 30 cycles using a Bioruptor Plus 
(Diagenode SA, Liège, Belgium) with high power for alternating 30 seconds of on 
and off. Sonicated samples were checked for shearing of fragment length ranging 
200-400 bp and proceeded further. These were diluted with 600 μL of dilution buffer 
(150 mM NaCl, 20 mM EDTA (pH 8.0), 0.5 % sodium deoxycholate, 50 mM Tris-HCl 
(pH 8.0), 1% (v/v) NP-40, 20 mM Sodium Fluoride, with protease inhibitors). Pre-
clearing was done with 100 μL of 50% Sepharose 4B (GE Healthcare, Uppsala, 
Sweden) slurry in dilution buffer containing 0.1% SDS (with protease inhibitors) for 1 
hour at 4 °C.  
Pre-cleared chromatin was centrifuged and supernatant was further diluted 
with dilution buffer to reduce final SDS concentration to 0.1 % and incubated with 
corresponding antibody (Table S1) overnight at 4°C. 30 μL of BSA-blocked 50% 
Protein-A Sepharose slurry (GE Healthcare) were added to capture the specific 
chromatin complexes and incubated for 2 hours at 4°C. 
ChIP immune complexes were washed twice with dilution buffer with 0.1% 





deoxycholate, 100 mM Tris-Cl (pH 8.5), 1% (v/v) NP-40, 20 mM Sodium Fluoride, 
with protease inhibitors), twice with dilution buffer with 0.1% SDS and finally twice 
with 1 X TE buffer. Number of washes was reduced one time in each buffer for 
BRD4 ChIP.  
For ChIP-qPCR, washed beads and the input samples (stored after pre-
clearing) were added with 100 μL of 10% (w/v) Chelex 100 slurry (Bio-Rad) and 
vortexed for 10 sec, and incubated at 95 °C for 10 minutes. Reverse-crosslinking 
was done by incubating with Proteinase K (20 μg/μL, Invitrogen) at 55°C at 1,000 
rpm for 30 minutes and the enzyme was heat-inactivated at 95 °C for 10 minutes. 
After final centrifugation, immunoprecipitated DNA can be recovered. 
For ChIP-seq, RNase treatment was done by adding 0.2 μg/μL of RNase A 
(Qiagen) in Tris 10 mM pH 8 and incubating the samples for 30 minutes at 37 ̊C. 
After diluting the immunopreciptated complexes by a buffer containing 20 mM EDTA, 
100 mM Tris-HCl (pH 8) and 2% SDS without any protease inhibitors, reverse 
crosslinking was performed by adding 1 μL of Proteinase K (20 mg/ml) and 
incubating overnight at 65 ̊C for 800 rpm. After adding LiCl and linear polyacrylamide 
to precipitate DNA, DNA was isolated using phenol-chloroform-isoamyl alcohol 
mediated extraction. 
qPCRs were done for amplicons covering gene-specific TSS, transcribed 
regions (TR) or ERE specific ChIP primers (Supplemental table S3) using 45 cycles 
of amplification. For H3K27ac and BRD4, primers were designed adjacent to EREs 
according to published H3K27ac data (Theodorou et al., 2013). Standard curve was 
made using DNA from input samples and used for quantification of the samples. 
Background DNA was detected using a ChIP assay with blocked protein-A 
sepharose. For normalizing ChIP samples, input DNA was used. The readings were 






2.1.1.3. Supplementary figures 
 
Figure 2.I.S1A. Principal Component Analysis (PCA) plot showing the correlation between the 
replicates and conditions of RNA-sequencing. 12 samples of six different conditions are shown in the 
2D plane spanned by their first two principal components. 
 
Figure 2.I.S1B. Single gene–specific qPCR analyses in MCF-7 showing relative mRNA expression of 





BRD4 siRNA (siBRD4) or JQ1 treatment with vehicle (Veh) or estrogen (E2) induction. Relative 
mRNA expression was shown as “Rel. mRNA exp.”. * indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
Data are represented as mean +/- standard deviation. n=3. 
 
Figure 2.I.S1C. Heatmap made with log2-fold changes from RNA-sequencing of MCF-7 cells 
transfected with control, BRD4 siRNA or control siRNA with JQ1 treatment and induced with estrogen 





siRNA and vehicle treated. siBRD4+Veh denote BRD4 siRNA and vehicle treated samples relative to 
control siRNA with vehicle treatment. JQ1+Veh denotes control siRNA, JQ1 and vehicle treated 
samples relative to negative control siRNA with vehicle treatment. Only estrogen upregulated genes 
higher than 1.5 fold are shown. Adjusted p-value ≤ 0.05. 
 
Figure 2.I.S1D.  Heatmap made with log2-fold changes from RNA-sequencing of MCF-7 cells 





estrogen (E2). E2 denotes control siRNA and E2 treated samples relative to control siRNA with 
vehicle treatment. siBRD4+E2 denote BRD4 siRNA and vehicle treated samples relative to control 
siRNA with estrogen treatment. JQ1+E2 denotes control siRNA, JQ1 and vehicle treated samples 
relative to negative control siRNA with estrogen treatment. Only estrogen-downregulated genes lower 







Figure 2.I.S1E. Gene Set Enrichment Analysis (GSEA) of mRNA expression data from RNA-seq. X-
axes show the enrichment scores of each topmost gene sets of Molecular Signature Database 
(MSigDB - C2) of GSEA under each conditions. Nominal p-value ≤ 0.05, FDR ≤ 25%. Y-axes show 
the location of each gene in the complete gene set. They are sorted by correlation with log2 fold 
changes comparing different conditions. Rank of each gene in the ordered gene set is also mentioned 











Figure 2.I.S1F. Top 25 pathways of GSEA analyses under each condition are shown. Each pathway 
enriched is shown with size of the geneset, Enrichment Score (ES), Normalised Enrichment Score 






Figure 2.I.S1G. Single gene–specific qPCR analyses in Ishikawa showing relative mRNA expression 
of PGR, TGF-α, BRD4 and DHFR (house-keeping gene) upon negative control siRNA, (siCont) or 
BRD4 siRNA (siBRD4) treatment with vehicle (Veh) or estrogen (E2) induction. Relative mRNA 
expression was shown as “Rel. mRNA exp.”. * indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Data are 
represented as mean +/- standard deviation. n=3.  
 
Figure 2.I.S1H. Single gene–specific qPCR analyses in H1299 cells showing relative mRNA 
expression of KLF10, SERPINE1, SMAD7 and BRD4 upon negative control siRNA (siCont) or BRD4 





shown as “Rel. mRNA exp.”. * indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Data are represented as 
mean +/- standard deviation. n=3. 
 
Figure 2.I.S1I. Western blot analyses with specific antibodies on whole Ishikawa and H1299 protein 
extracts after transfection with negative control (siCont) or BRD4 siRNA (siBRD4) with estrogen 












Figure 2.I.S1J. Single gene–specific qPCR analyses in MCF7 showing relative mRNA expression of 
ESR1 upon negative control siRNA (siCont), BRD4 siRNA (siBRD4) or JQ1 treatment with vehicle 
(Veh) or estrogen (E2) induction. Upper panel shows ESR1 expression after JQ1 treatment 2.5 hours 





after BRD4 knockdown. Relative mRNA expression was shown as “Rel. mRNA exp.”. * for p ≤ 0.05, ** 
for p ≤ 0.01, *** for p ≤ 0.001. Data are represented as mean +/- standard deviation. n=3. 
 
Figure 2.I.S2A.  Statistical significance of proliferation based cell counting assay in MCF7 after 
negative control siRNA (siCont), BRD4 siRNA (siBRD4), JQ1 and ICI182780 (ICI) with vehivle (Veh) 
or estrogen treatment (E2) after 3, 5 and 7 days shown in Fig 2A. One way ANOVA was performed 
with Tukey HSD based multiple comparisons using SPSS package and p-values were calculated. 






Figure 2.I.S2B. Proliferation based crystal violet assays in Ishikawa showing the proliferation defect 
under estrogen induced conditions with negative control siRNA (siCont) or BRD4 siRNA (siBRD4) and 
DMSO or JQ1 treatment. Percentage of intensity (area and density) covered by the cells after 7-9 
days of growth were quantified using ImageJ with a plugin ColonyArea. The data is represented as 
mean +/- standard deviation. n=2. 
 
Figure 2.I.S2C. Three week-old mice injected with vehicle (Cont) or JQ1 for 3 weeks were analyzed 
for their difference in body weight. X-axis shows the time-course of treatment in days and Y-axis 
shows the average body weight in grams. The data is represented as mean +/- standard deviation. 






Figure 2.I.S3A. Correlation plots of BRD4 ChIP signals of different replicates and conditions - vehicle 
(veh) and estrogen (E2) on all regions and specifically on distal EREs, estrogen upregulated gene-







Figure 2.I.S3B.  ChIP-qPCR analyses of BRD4 recruitment to GREB1, XBP1 and TFF1 TSS after 
DMSO or JQ1 treatment with vehicle (Veh) or estrogen (E2) induction. * indicates p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001. Data are represented as mean +/- standard deviation. n=3. Dotted line indicates 
background. The right panel shows the genomic profile of BRD4 on XBP1 after vehicle (Veh) or 
estrogen (E2) induction. 
 
Figure 2.I.S3C. Average percentage of BRD4 ChIP enrichment signals over specific genomic 
features like promoters, 5’ UTR, 3’ UTR, Coding exon, introns and distal regions. Significance of 






Figure 2.I.S3D. Average BRD4 ChIP enrichment profiles were compared for all TSS, E2 upregulated, 
downregulated and nonregulated gene-specific TSS under vehicle (Veh) and estrogen (E2) treated 
conditions. X-axis shows the distance from TSS in base pairs. TSS is marked with a black dotted line. 
Y-axis shows the average BRD4 signal of the reads normalized per hundred million base pairs.  
 
Figure 2.I.S3E. Heatmap profiles of BRD4 after vehicle (Veh) and estrogen (E2) treatment on regions 







Figure 2.I.S3F. Aggregate plots showing genomic binding profiles of BRD4 on all TSS and estrogen-
downregulated genes upon vehicle (Veh) and estrogen (E2) treated conditions. X-axis shows the 
distance from TSS in base pairs. Y-axis shows the average BRD4 signal of the reads normalized per 
hundred million base pairs. TSS is marked with a black dotted line.  
 
Figure 2.I.S3G. Heatmap profiles of BRD4 after vehicle (Veh) and estrogen (E2) treatment on regions 






Figure 2.I.S3H. Correlation plots of H2Bub1 ChIP signals of different replicates and conditions - 
vehicle (veh) and estrogen (E2) on all regions and specifically on distal EREs, estrogen upregulated 
gene-specific TSS and all TSS.  
 
Figure 2.I.S3I. ChIP-qPCR analyses of H2Bub1 on GREB1, TFF1 and GAPDH transcribed regions 





** p ≤ 0.01, *** p ≤ 0.001. Data are represented as mean +/- standard deviation. n=3. Dotted line 
indicates background. 
 
Figure 2.I.S3J. Average percentage of H2Bub1 ChIP enrichment signals over specific genomic 
features like promoters, 5’ UTR, 3’ UTR, Coding exon, introns and distal regions. Both genome and 
ChIP enrichments were compared. 
 
Figure 2.I.S3K. Single gene profiles of H2Bub1 on estrogen induced genes (GREB1, XBP1 and 







Figure 2.I.S3L. Aggregate plots showing genomic profiles of H2Bub1 on all TSS, estrogen-
nonregulated and downregulated genes upon vehicle (Veh), JQ1 as well as vehicle (JQ1 Veh), 
estrogen (E2) and JQ1 as well as estrogen (JQ1 E2) treated conditions. X-axis shows the distance 
from TSS in kilobase pairs. Y-axis shows the average H2Bub1 signal of the reads normalized per 
hundred million base pairs. TSS is marked with a black dotted line.  
 
Figure 2.I.S3M. Average ChIP enrichment profiles of H2Bub1 were compared for all TSS, E2 





(E2) treated conditions. X-axis shows the distance from TSS in base pairs. TSS and gene end are 
marked with a black dotted line. Y-axis shows the average H2Bub1 signal of the reads normalized per 
hundred million base pairs. 
 
Figure 2.I.S3N. Aggregate plots showing genomic profiles of H2Bub1 on estrogen-upregulated genes 
grouped according to RNAPII occupancy (RNAPII recruited de novo, RNAPII prebound and recruited 
and RNAPII constitutively bound) upon vehicle (Veh), JQ1 as well as vehicle (JQ1 Veh), estrogen 
(E2) and JQ1 as well as estrogen (JQ1 E2) treated conditions. X-axis shows the distance from TSS in 
kilobase pairs. Y-axis shows the average H2Bub1 signal of the reads normalized on hundred million 





gene - 1.5 to 2.5 kb downstream of each TSS were used to calculate the p-values using ANOVA with 
multiple regression models between conditions. * indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, n.s - 
not significant.  
 
Figure 2.I.S3O. Correlation plot on all TSS + 3 kb showing the association of BRD4, H3K27ac, 
H3K4me3, nascent RNA transcription (GRO-seq), RNAPII, H2Bub1 and DNaseI hypersensitivity sites 
(DNase-seq) and H3K27me3.  
 
Figure 2.I.S3P. Aggregate plot analyses of H3K4me3, DNaseI hypersensitivity sites (DNase-seq) and 





regulated genes. “High” group corresponds to estrogen-upregulated TSS having weighted average of 
GRO-seq signal greater than 0.3; “medium” ≥ 0.15 < 0.3; “low” > 0 < 0.15; “null” with no value of 
average.  
 
Figure 2.I.S3Q. Aggregate plot analyses of BRD4, H3K27ac, RNA expression (GRO-seq), RNAPII 
occupancy, H2Bub1, H3K4me3, DNaseI hypersensitivity sites (DNase-seq) and H3K27me3 on GRO-
seq based classified (High, Medium, Low and Null) all TSS sites. “High” group corresponds to all TSS 
having weighted average of GRO-seq signal greater than 0.3; “medium” ≥ 0.15 < 0.3; “low” > 0 < 0.15; 
“null” with no value of average. A class of H3K27me3-positive summits was examined as a negative 






Figure 2.I.S3R. Heatmap profiles of BRD4 and H3K27ac, nascent RNA transcription (GRO-seq), 
RNAPII, H2Bub1, H3K4me3, DNaseI hypersensitivity sites (DNase-seq) and H3K27me3 on 1 kb 
upstream and 5 kb downstream of all TSS aligned from high to null GRO-seq signals. TSS and +5 kb 
are marked. 
  
Figure 2.I.S4A. Western blot analyses with ERα and β–actin specific antibodies on whole MCF-7 






Figure 2.I.S4B. ChIP-qPCR analyses of ERα recruitment to XBP1 and TFF1 ERE after DMSO or JQ1 
treatment with vehicle (Veh) or estrogen (E2) induction. * indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
Data are represented as mean +/- standard deviation. n=3. Dotted line indicates background. 
  
Figure 2.I.S4C. ChIP-qPCR analyses of RAD21 recruitment to GREB1, XBP1 and TFF1 ERE after 
DMSO or JQ1 treatment with vehicle (Veh) or estrogen (E2) induction. * indicates p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001. Data are represented as mean +/- standard deviation. n=3. Dotted line indicates 
background. 
 
Figure 2.I.S4D. Heatmap profiles of ERα under estrogen (E2) and JQ1 as well as estrogen (JQ1 E2) 






Figure 2.I.S4E. Correlation plots of ERα ChIP signals of different replicates and conditions - estrogen 
(E2) and JQ1 as well as estrogen (JQ1 E2) on all regions and specifically on distal EREs. 
 
Figure 2.I.S4F. Genomic binding profiles of ERα on estrogen induced genes (GREB1, XBP1 and 






Figure 2.I.S4G. Venn diagram showing overlap in binding regions of ERα and BRD4. The number of 
regions is written inside the circles. 
 
Figure 2.I.S4H. ChIP-qPCR analyses of H3K27ac on XBP1 and TFF1 ERE overlapping region and 
TSS after DMSO or JQ1 treatment with vehicle (Veh) or estrogen (E2) induction. * indicates p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.001. Data are represented as mean +/- standard deviation. n=3. Dotted line 
indicates background. 
 
Figure 2.I.S4I. ChIP-qPCR analyses of BRD4 recruitment to GREB1, XBP1 and TFF1 ERE after 
DMSO or JQ1 treatment with vehicle (Veh) or estrogen (E2) induction. * indicates p ≤ 0.05, ** p ≤ 







Figure 2.I.S4J. Heatmap profiles of BRD4 under estrogen (E2) and JQ1 as well as estrogen (JQ1 E2) 
treatment on distal EREs +/- 5 kb. Center of each heatmap denotes center of distal EREs.  
 
Figure 2.I.S4K. Aggregate plot analyses of DNase I hypersensitivity sites (DNase-seq) and 
H3K27me3 on GRO-seq based classified (High, Medium, Low and Null) TSS sites on distal EREs. 
“High” group corresponds to distal EREs having weighted average greater than 0.45; “medium” > 0.25 
< 0.45; “low” > 0 ≤ 0.25; “null” with no value of average. A class of H3K27me3-positive summits was 






Figure 2.I.S4L. Heatmap profiles of DNase I hypersensitivity sites (DNase-seq) and H3K27me3 on 
distal EREs aligned from high to null GRO-seq signals. Center of each heatmap denotes center of 






Figure 2.I.S4M. Binding profiles of BRD4, H3K27ac (purple), ERα (light blue) and GRO-seq (pink) on 
XBP1 and TFF1 distal EREs and promoter. BRD4 with red peaks indicates estrogen (E2) treated and 






Figure 2.I.S4N. Heatmap showing genomic binding profiles of RNAPII on distal EREs which produce 
high eRNA (GRO-seq group “high”) upon vehicle (veh) and estrogen (E2) treated conditions. 
 
Figure 2.I.S4O. ChIP-qPCR analyses of RNAPII PSer2 occupancy on GREB1 3’ end after DMSO or 
JQ1 treatment with vehicle (Veh) or estrogen (E2) induction. * indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
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 Hormone-dependent gene expression requires dynamic and coordinated 
epigenetic changes. Estrogen receptor-positive (ER+) breast cancer is particularly 
dependent upon extensive chromatin remodeling and changes in histone 
modifications for the induction of hormone-responsive gene expression. Our 
previous studies established an important role of bromodomain-containing protein-4 
(BRD4) in promoting estrogen-regulated transcription and proliferation of ER+ breast 
cancer cells. Here, we investigated the association between genome-wide 
occupancy of histone H4 acetylation at lysine 12 (H4K12ac) and BRD4 in the context 
of estrogen-induced transcription. Similar to BRD4, we observed that H4K12ac 
occupancy increases near the transcription start sites (TSS) of estrogen-induced 
genes as well as at distal ERα binding sites in an estrogen-dependent manner. 
Interestingly, H4K12ac occupancy highly correlates with BRD4 binding and enhancer 
RNA production on ERα-positive enhancers. Consistent with an importance in 
estrogen-induced gene transcription, H4K12ac occupancy globally increased in ER-
positive cells relative to ER-negative cells and these levels were further increased by 
estrogen treatment in an ERα-dependent manner. Together, these findings reveal a 
strong correlation between H4K12ac and BRD4 occupancy with estrogen-dependent 
gene transcription and further suggest that modulators of H4K12ac and BRD4 may 
serve as new therapeutic targets for hormone-dependent cancers. 
Introduction 
The estrogen receptor-alpha (ERα) plays a central role in determining a 
luminal epithelial phenotype and tumor progression in a large fraction of breast 
cancers. Notably, interfering with ERα-regulated gene transcription represents a 
major therapeutic target in breast cancers where anti-estrogen therapies are the 
primary indicated therapy for patients with ERα-positive tumors. Estrogen-mediated 
gene induction is tightly and dynamically regulated. Stimulation with estrogen 
induces the binding of ERα to estrogen response elements (EREs), which act as 
enhancers in a manner largely dependent upon the pioneer factor, Forkhead protein 
A-1 (FOXA1) (Carroll et al., 2005; Hurtado et al., 2011). Upon activation, ERα further 





including SRC1/NCOA1 (Liu et al., 1999). SRC1 further interacts with and recruits 
additional HATs such as p300 and CBP (Demarest et al., 2002; Kamei et al., 1996). 
Additionally, ERα also recruits another HAT, p300/CBP-associated factor (PCAF) 
(Blanco et al., 1998). Recruitment of HATs to EREs promotes histone acetylation 
and thereby leads to gene induction (Green and Carroll, 2007). In particular, 
acetylation of H3K27 and H4K16 are found near transcriptional start sites (TSS) as 
well as on active enhancer regions where their occupancy is tightly associated with 
the recruitment of bromodomain protein-4 (BRD4) (Creyghton et al., 2010; Zhang et 
al., 2012a; Nagarajan et al., 2014; Zippo et al., 2009; Belikov et al., 2012). 
BRD4 belongs to the bromo- and extraterminal (BET) domain protein family 
and serves as a major epigenetic reader of histone acetylation. BRD4 preferentially 
binds to multiple acetylated lysine residues including K5, K8, K12 and K16 of histone 
H4 (Jung et al., 2014; Zhang et al., 2012a) and functions to recruit and activate 
Cyclin-Dependent Kinase-9 (CDK9), the kinase component of Positive Transcription 
Elongation Factor-b (P-TEFb) (Yang et al., 2005). CDK9 in turn promotes 
transcriptional elongation by phosphorylating serine 2 of the C-terminal heptapeptide 
repeat of RNA polymerase (RNAPII) as well as subunits of the Negative Elongation 
Factor (NELF) and DRB Sensitivity-Inducing Factor (DSIF) complexes (Ping and 
Rana, 2001; Pirngruber et al., 2009a; Yamaguchi et al., 1999). Notably, RNAPII Ser2 
phosphorylation serves as a hallmark for transcriptional elongation and serves as a 
platform for the co-transcriptional recruitment of chromatin-modifying enzymes 
including the RNF20/40 ubiquitin ligase complex, which catalyzes the 
monoubiquitination of histone H2B at lysine 120 (H2Bub1) in the transcribed region 
of active genes (Karpiuk et al., 2012; Minsky et al., 2008; Pirngruber et al., 2009a). 
Addition of ubiquitin is hypothesized to topologically open chromatin structure (Fierz 
et al., 2011) and promote transcriptional elongation (Karpiuk et al., 2012; Pavri et al., 
2006; Pirngruber et al., 2009a). In addition to its role in recruiting CDK9 to acetylated 
chromatin, BRD4 has also been reported to exhibit intrinsic kinase activity and 
directly phosphorylate RNAPII-PSer2 (Devaiah et al., 2012). These findings support 
a role for BRD4 in promoting gene expression by binding to acetylated histones and 
promoting RNAPII elongation in a chromatin context. This effect appears to be, at 
least in part, dependent upon CDK9 and BRD4 recruitment to enhancers (Lovén et 





RNAs from enhancer elements (eRNAs) which are required for induced gene 
transcription and chromosomal looping (Hah et al., 2013; Kaikkonen et al., 2013; Li 
et al., 2013; Nagarajan et al., 2014; Kanno et al., 2014). 
A number of studies have uncovered an essential role for BRD4 in various 
malignancies including Myc-driven cancers (Delmore et al., 2011; Ott et al., 2012), 
leukemia (Herrmann et al., 2012; Lockwood et al., 2012), lymphoma (Chapuy et al., 
2013), lung adenocarcinoma (Lockwood et al., 2012), prostate (Asangani et al., 
2014) and breast cancers (Crawford et al., 2008; Feng et al., 2014; Nagarajan et al., 
2014). BRD4 was also reported to regulate metastasis in breast cancer (Alsarraj et 
al., 2011). Consistently, a BRD4-regulated gene signature was reported to predict 
outcome and survival in breast cancer, especially ER-positive breast cancer (Alsarraj 
et al., 2011; Crawford et al., 2008). Moreover, BRD4 is required for the growth of 
ERα-positive tamoxifen-resistant breast cancer where it functions to promote ERα-
dependent gene transcription (Feng et al., 2014). In addition to these findings, our 
recent studies also show that BRD4 and downstream histone H2B 
monoubiquitination are central regulators of estrogen-responsive transcription (Bedi 
et al., 2015; Nagarajan et al., 2014; Prenzel et al., 2011). BRD4 is recruited to 
promoters and enhancers of ERα-dependent genes following estrogen stimulation to 
regulate estrogen-induced transcription and is required for estrogen-dependent 
proliferation (Nagarajan et al., 2014). However, the epigenetic mechanisms 
controlling BRD4 recruitment to estrogen responsive genes and EREs is poorly 
understood. 
In this study, we examined the association of H4K12ac with BRD4 occupancy 
genome-wide and analyzed its function in estrogen-regulated transcription. We show 
that H4K12ac occupies estrogen-responsive gene promoters and EREs in an 
inducible manner (Nagarajan et al., 2014) where its occupancy significantly 
correlates with BRD4 binding, H2Bub1 occupancy, mRNA expression as well as 
eRNA synthesis. We also observed higher global levels of H4K12ac in ERα-positive 
breast cancer cells compared to ERα-negative mammary epithelial cells and a 
further estrogen-dependent increase in ERα-positive cells which was decreased by 
anti-estrogen treatment. Together these results identify H4K12ac as a potential 






H4K12ac correlates with BRD4 binding and active transcription on estrogen-
induced genes 
 In order to determine whether H4K12ac may play a role in estrogen-
responsive gene expression, we performed genome-wide ChIP-sequencing analyses 
of H4K12ac with or without estrogen treatment in the ERα-positive MCF7 luminal 
breast cancer cell line. Aggregate profiles and heatmap analyses showed that 
estrogen induction increases H4K12ac occupancy near the transcription start sites 
(TSS) (Figure 2.II.1A-B, 2.II.S1A-B). Interestingly, this resembled the increased 
recruitment of BRD4 adjacent to TSS of estrogen-responsive genes (Nagarajan et 
al., 2014). We further performed correlation and heatmap analyses to determine 
whether H4K12ac occupancy is correlated with BRD4 (Nagarajan et al., 2014) 
recruitment, RNAPII (Welboren et al., 2009) occupancy as well as various other 
histone modifications. Specifically, we compared H4K12ac occupancy to that of 
H3K27ac (Theodorou et al., 2013) and H3K4me3 (Joseph et al., 2010) which are 
both active marks of transcription initiation, H2Bub1 (Nagarajan et al., 2014) which 
correlates with transcriptional elongation and is dependent upon BRD4 activity 
(Nagarajan et al., 2014) and GRO-seq (Global run on-sequencing) (Hah et al., 2013) 
which represents nascent RNA transcription. H3K27me3 (Joseph et al., 2010) was 
used as a negative control and a repressive mark for transcription. Heatmaps were 
arranged in descending order according to the H3K27ac signals near TSS (TSS and 
3 kb downstream). These analyses revealed a high correlation between H4K12ac 
and BRD4 occupancy and to a lesser extent with H3K27ac occupancy (Figure 
2.II.1C-D, 2.II.S1C-D). Furthermore, consistent with their common association with 
active gene transcription, H3K4me3 and H2Bub1 displayed highest correlations with 
H4K12ac and BRD4. Interestingly, H4K12ac levels did not decrease near the TSS of 
estrogen-downregulated genes (Figure 2.II.S1D-E). These effects are consistent with 
the negligible change in BRD4 binding on estrogen-repressed genes after estrogen 
treatment and indicate that histone deacetylase-mediated removal of H4K12ac may 
occur slower than the transcriptional repression of these genes (Nagarajan et al., 
2014).  Altogether these results uncover a high correlation between H4K12ac and 






Figure 2.II.1: H4K12ac correlates with BRD4 binding in estrogen-induced transcription. (A) 
Average genomic binding profiles of H4K12ac around TSS and 3 kb upstream and downstream of 
estrogen-induced genes under vehicle (Veh) and estrogen-treated (E2) conditions. The X-axis shows 
the distance from the TSS of the genes in kilobase pairs. TSS is indicated by a black dotted line. (B) 
Heatmaps showing genomic binding profiles of H4K12ac around TSS and 3 kb upstream and 
downstream of estrogen-induced genes under vehicle (Veh) and estrogen-treated (E2) conditions. 
Center of the heatmap represents TSS. Color key of the heatmaps is shown on the side.  (C) 
Correlation plot showing the heatmap with the Pearson’s correlation coefficient values for H4K12ac, 
BRD4, H3K27ac, H3K4me3, H2Bub1, GRO-seq, RNAPII and H3K27me3 on TSS and 3 kb 
downstream region of estrogen-upregulated genes. Color key of the heatmap is shown at the bottom 
of the plot. (D) Heatmaps showing genomic binding profiles of H3K27ac, H4K12ac with estrogen 
treatment (H4K12ac E2) and without estrogen treatment (H4K12ac Veh), BRD4, nascent RNA 
transcription (GRO-seq), RNAPII, H2Bub1, H3K4me3 and H3K27me3 around TSS and 3 kb upstream 





H3K27ac signals from high to low. Center of the heatmap represents TSS. Color key of the heatmaps 
is shown at their side.  
H4K12ac is associated with enhancer function 
 Given the association of BRD4 with enhancers (Chapuy et al., 2013; Lovén et 
al., 2013) and its recently established role in promoting eRNA transcription 
(Kaikkonen et al., 2013; Nagarajan et al., 2014; Kanno et al., 2014), we examined 
whether H4K12ac occupancy is also preferentially enriched on ERα- and FOXA1-
bound enhancers. Indeed, we observed H4K12ac enrichment on distal EREs and 
this enrichment significantly increased following estrogen treatment as shown in 
aggregate plot and heatmap analyses (Figure 2.II.2A-B). To further examine the 
association of H4K12ac at distal ERα-bound enhancers, correlation plot and 
heatmaps were generated for BRD4, as well as ERα, FOXA1 and H3K27ac on these 
regions (Figure 2.II.2C, 2.II.S2A). We observed that BRD4 and H3K27ac occupancy 
correlated with H4K12ac on distal enhancers. Notably, apart from its association with 
FOXA1 and BRD4, ERα binding correlated particularly well with H4K12ac and lesser 
with H3K27ac. Interestingly, RNAPII occupancy and nascent RNA transcription on 
enhancers, which are indicative of eRNA production, also correlated with H4K12ac 
occupancy. Genomic Regions Enrichment of Annotations Tool (GREAT) analyses 
(McLean et al., 2010) on distal intergenic regions which exhibited overlapping peaks 
of H3K27ac, H4K12ac and BRD4 demonstrated an enrichment of estrogen and 
breast cancer luminal upregulated and basal downregulated-related pathways 
(Figure 2.II.S2B-C). These findings support a strong association among H4K12ac, 
H3K27ac, BRD4 and ERα function on distal enhancer regions.  
 To further evaluate the association of H4K12ac with distal enhancer function, 
distal EREs were grouped into four classes (high, medium, low and null) according to 
the enrichment of H4K12ac around EREs. Consistent with their potential function as 
active enhancers, these groups of distal regions also correlated with BRD4 and 
RNAPII occupancy as well as nascent RNA transcription (Figure 2.II.2D). Together 
these findings demonstrate that H4K12ac occupies active EREs which are bound by 






Figure 2.II.2: H4K12ac correlates with BRD4 binding in estrogen-induced enhancer function. 
(A) Average genomic binding profiles of H4K12ac around distal EREs and 5 kb upstream and 
downstream under vehicle (Veh) and estrogen-treated (E2) conditions. X-axis shows the distance 
from distal EREs in kilobase pairs. Center of ERE is marked with black dotted line. (B) Heatmaps 
showing genomic binding profiles of H4K12ac around ERE and 5 kb upstream and downstream under 
vehicle (Veh) and estrogen-treated (E2) conditions. Center of the heatmap represents center of ERE. 
Color key of the heatmaps is shown on the side.  (C) Correlation plot showing the heatmap with the 
Pearson’s correlation coefficient values for H4K12ac, BRD4, H3K27ac, ERα, FOXA1, GRO-seq, 





induced genes. Color key of the heatmap is shown at the bottom of the plot. (D) High, medium, low 
and null groups were classified according to the H4K12ac signal under estrogen-treated conditions 
and then heatmaps were plotted for various ChIP-seq signals (H4K12ac E2, BRD4, nascent RNA 
transcription (GRO-seq), RNAPII, ERα, FOXA1 and H3K27me3) around distal EREs and 5 kb 
upstream and downstream. Center of the heatmap represents center of the distal ERE region. Color 
key of the heatmaps is shown on the side. 
H4K12ac correlates with BRD4 function in gene regulation  
 
Figure 2.II.3: H4K12ac correlates with BRD4 function in regulating gene expression. (A) Boxplot 
showing the absolute gene expression in logarithmic values of normalized counts (log reads of Abs. 
exp.) under vehicle treated conditions. Genes which are independent (I) and downregulated (D) 
following BRD4 depletion (siBRD4) are shown. siCont refers to negative control siRNA treated 
samples. p-values were calculated using Mann-Whitney test and are shown only for significant 
changes. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05; (B) Boxplots showing the average ChIP-seq signal in 
logarithmic values (log avg. read density) of RNAPII, H2Bub1, H4K12ac, H3K27ac, BRD4, H3K4me3 





downregulated (D) following BRD4 depletion (siBRD4) are shown. siCont refers to negative control 
siRNA treated samples. p-values were calculated using Mann-Whitney test were shown only for 
significant changes. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05. 
In order to investigate a potential association with the function of BRD4, the 
average intensity of BRD4, H4K12ac, H3K27ac, H3K4me3, H2Bub1 and RNAPII 
downstream of the TSS (TSS and 3 kb downstream) were calculated on genes 
whose expression either decreased (“downregulated”) or was unaffected 
(“independent”) upon BRD4 depletion under vehicle treated conditions from our 
previously published RNA sequencing data. Interestingly, genes whose expression 
decreased following BRD4 depletion were lower expressed than non-regulated 
genes prior to knockdown (Figure 2.II.3A) and also displayed lower levels of RNAPII 
(Figure 2.II.3B). Consistent with lower RNAPII occupancy, H4K12ac and H2Bub1 
occupancy were also lower on BRD4-dependent genes compared to BRD4-
independent genes (Figure 2.II.3B). These results further suggest a cooperative 
function between H4K12ac and BRD4 in controlling RNAPII and co-transcriptional 
H2B monoubiquitination to regulate a defined subset of inducible genes. 
H4K12ac occupancy correlates with gene expression levels 
 In order to further validate the association of H4K12ac with active gene 
transcription, average signals of the active transcription marks around TSS were 
compared with the normalized counts of expression for each gene. As shown in 
scatterplots along with the respective correlation coefficients, H2Bub1, RNAPII, 
H3K4me3 and H4K12ac significantly correlated with mRNA expression (Figure 2.II.4, 
2.II.S3-4). Together these results support a model in which a H4K12ac-BRD4-
RNAPII-H2Bub1 axis directs overall gene expression, especially in estrogen-induced 
transcription.  
Estrogen promotes global H4K12ac 
 As H4K12ac occupancy is closely associated with ERα-dependent gene 
activity, we also compared H4K12ac occupancy in ERα-positive MCF7 breast cancer 
cells to that in the ER-negative MCF10A normal mammary epithelial cell line both in 
ChIP and in whole cell protein lysates.  Both single gene ChIP-qPCRs as well as 






Figure 2.II.4: H4K12ac positively correlates with gene expression. Scatterplots showing the 
relationship between various ChIP-seq signals  (average signal over input of H4K12ac, H3K4me3, 
BRD4, H2Bub1, RNAPII, GRO-seq, H3K27ac, H3K27me3, logarithmic fold changes of siBRD4 
compared to siCont (Log2FC)) and absolute gene expression in logarithmic values. Pearson 
correlation coefficient (R) values and two-tailed p-values were shown above the plot. Each dot in the 
plot represents a single gene. Red line indicates the correlation.  
comparing to MCF10A around TSS of estrogen-dependent genes (Figure 2.II.5A-B). 
Surprisingly, this effect was also observed near the TSS of estrogen-independent 
genes (Figure 2.II.5C-D) as well as at both distal H3K27ac-positive regions from 
MCF7 and MCF10A and regions occupied by H3K27ac, but not ERα (Figure 2.II.5F-





estrogen fulvestrant, which rapidly reduces ERα protein levels via proteosomal 
degradation (Eckert et al., 1984; Wakeling and Bowler, 1992), decreases H4K12ac 
occupancy on estrogen-dependent and independent genes (Figure 2.II.5B, 2.II.5.D). 
Together, these studies suggested that H4K12ac levels may globally depend upon 
ERα activity. Consistently, Western blot analyses confirmed that H4K12ac globally 
increased after estrogen treatment in MCF7 cells and decreased following fulvestrant 
treatment (Figure  2.II.5E). Notably, H4K12ac levels were the lowest in ER-negative 
MCF10A cells. These results suggest a potential specific role of H4K12ac in 
estrogen-induced transcription and correlation with ERα status.   
 
Figure 2.II.5: H4K12ac depends upon ERα activity. (A, C, F, G)  Average genomic binding profiles 
of H4K12ac in vehicle- (Veh) and estrogen-treated (E2) MCF7 or MCF10A cells around TSS and 3 kb 
upstream and downstream of estrogen upregulated genes (A), TSS and 3 kb upstream and 
downstream of estrogen-independent genes (C) distal H3K27ac-positive regions and 5 kb upstream 





(ER negative (-ve)) and 5 kb upstream and downstream of them (G). X-axis shows the distance from 
the TSS (A, C) or center of the distal H3K27ac-positive region (B, D) in kilobase pairs. TSS or center 
of H3K27ac peak is indicated by a black dotted line. (B, D) ChIP-qPCR analyses of H4K12ac in 
vehicle- (Veh), estrogen-treated (E2) and/or ICI-182,780 (ICI) treated MCF7 or MCF10A cells on TSS 
of respective estrogen-dependent (GREB1, CXCL12 and XBP1) (B) and estrogen-independent genes 
(RPLP0, GAPDH and HNRNPK) (D). H4K12ac enrichment is denoted by percentage of input values. 
Dotted line indicates background DNA precipitated by negative control IgG antibody. (E) Western blot 
analyses showing ERα, β-actin, H4K12ac and H3 levels in vehicle- (Veh), estrogen-treated (E2) 
and/or ICI-182,780 (ICI) treated MCF7 or MCF10A cells. H4K12ac levels were normalized with H3 
and the values were shown under the blot.  
Discussion 
 Signal-induced transcription requires a highly coordinated and complex 
interplay between various transcription factors, post-translational histone 
modifications, epigenetic readers and chromatin remodelers in order to induce gene 
expression in a proper temporal and spatial manner. Dysregulation of these 
mechanisms frequently results in disorders such as cancer. Positive association of 
H4K12ac with estrogen-induced gene transcription reveals a potentially important 
and specific role of this modification in promoting ERα-induced gene transcription. 
According to our model, ERα-directed H4K12 acetylation facilitates the recruitment of 
BRD4 to both enhancers and promoters. Subsequently, BRD4 recruits CDK9 in 
order to promote eRNA synthesis at enhancers and transcriptional elongation of 
ERα-dependent mRNAs. The latter occurs, at least in part via phosphorylation of 
RNAPII at serine-2 and the subsequent monoubiquitination of histone H2B, which 
may help to open chromatin structure and facilitate the activity of other chromatin-
associated elongation factors (Bedi et al., 2015; Nagarajan et al., 2014; Pavri et al., 
2006; Prenzel et al., 2011).  
Transcriptional activation is tightly coupled with histone acetylation (Allfrey et 
al., 1964; Grunstein, 1997; Struhl, 1998). However, the mechanisms linking histone 
acetylation and ERα-dependent transcriptional activation are not completely 
understood. Here, we show that H4K12ac is globally increased across the ERα 
cistrome in response to estrogen induction. This supports the dynamic nature of 
histone acetylation including H4K12ac upon estrogen treatment (Sun et al., 2001; 





p300/CBP (Bowers et al., 2010; Ogryzko et al., 1996), which is a critical determinant 
of ERα-regulated transcription (Kim et al., 2001; Liu et al., 1999). Thus, our findings 
not only validate the role of histone acetyltransferases like p300 in hormone-
dependent systems (Kim et al., 2001; Liu et al., 1999), but also provide a further 
potential mechanistic explanation linking H4K12ac to BRD4 recruitment to estrogen-
responsive enhancers and TSS. Thus, H4K12ac may play a central role in 
transcriptional activation which links ERα binding to the subsequent recruitment of 
other epigenetic regulators like BRD4, which are essential for ERα activity.  
 The transcriptional mechanisms controlling stimuli-induced gene expression is 
tightly coupled to the rapid association and disassociation of transcriptional factor 
and cofactor complexes as well as dynamic changes in chromatin remodeling and 
histone modifications (Green and Carroll, 2007; Johnsen, 2012; Métivier et al., 2006; 
Voss and Hager, 2014). Interestingly, we show that the genes which are dependent 
upon BRD4 exhibit reduced expression and lower RNAPII occupancy than BRD4-
independent genes. This could support the possibility that these genes may have a 
higher turnover of the transcriptional activation complexes. Consistent with the lower 
expression and RNAPII occupancy, H4K12ac and H2Bub1 occupancy on these 
genes were also lower compared to BRD4-independent genes and their levels were 
highly dynamic during estrogen-induced transcription. Pathway analyses of BRD4-
regulated genes (Nagarajan et al., 2014) as well as genes associated with enhancer 
regions which are co-bound by H3K27ac, H4K12ac and BRD4 revealed a specific 
enrichment of estrogen-induced genes. Consistently, estrogen-responsive genes 
display a highly dynamic and ERα-dependent assembly and disassembly of 
transcription factor and co-factor complexes which determine the magnitude and 
duration of gene induction (Métivier et al., 2006). Together these results suggest that 
estrogen-inducible genes may differentially depend upon BRD4 and its associated 
up- and downstream epigenetic regulatory mechanisms are based on a necessity for 
dynamic recruitment of transcriptional cofactors, RNAPII, post-translational 
modification of histones and chromatin remodeling.  
  Previous studies have suggested that BRD4 predominantly binds to histone 
H4 acetylated at lysine residues 5, 8, 12 and 16 (Jung et al., 2014; Zhang et al., 





regulating transcriptional activity is less established (Zippo et al., 2009). Our studies 
demonstrate a strong link between the dynamic nature of H4K12ac and BRD4 and 
their association with RNAPII and H2Bub1 during target gene activation.  
 Induced occupancy of H4K12ac at both TSS and enhancers in cancer cells 
support a role for histone acetylation and enhancer activity in ERα-dependent cancer 
progression. Moreover, we describe a significant correlation between histone 
acetylation and eRNA production, which can control targeted gene induction in 
various disease-specific conditions (Hah et al., 2013; Kaikkonen et al., 2013; Li et al., 
2013; Nagarajan et al., 2014). Notably, given the potential utility of BET domain 
inhibitors for the treatment of various cancers (Chapuy et al., 2013; Delmore et al., 
2011; Herrmann et al., 2012; Lockwood et al., 2012; Lovén et al., 2013; Ott et al., 
2012), these findings provide additional insight into the molecular mechanisms by 
which BRD4 functions in ERα-regulated gene transcription. Considering the recent 
demonstration of the utility of BET inhibition in the treatment of tamoxifen-resistant 
and hormone-dependent cancers (Asangani et al., 2014; Feng et al., 2014; 
Nagarajan et al., 2014), our studies provide a better understanding into the 
mechanism controlling BRD4 activity in this system. Importantly, BRD4 inhibition 
along with Fulvestrant sensitizes tumors for their growth inhibition in tamoxifen-
resistant xenograft models (Feng et al., 2014) and our studies show that Fulvestrant 
rapidly reduces H4K12ac. This opens up a possibility of significant H4K12ac 
occupancy in tamoxifen-resistant breast cancers bringing up the therapeutic 
importance of H4K12ac and combined therapies with BRD4 inhibition and anti-
estrogens in these cancers.  Combination of HDAC inhibitors with tamoxifen is 
implicated in reversing tamoxifen/aromatase inhibitor-resistance in ER-positive 
breast cancers and HDAC inhibitors were shown to increase the sensitivity of cells to 
BRD4 inhibition for blocking cell growth and promoting apoptosis in leukemia and 
lymphoma  (Bhadury et al., 2014; Fiskus et al., 2014; Munster et al., 2011).  This 
may potentially provide a rationale for testing specific modulators of BRD4 
recruitment to chromatin (e.g., inhibitors of histone deacetylases or histone 
acetyltransferases which particularly modulate H4K12ac) in regulating hormone-








MCF7 cells were kindly provided by K. Effenberger (University Medical 
Center, Hamburg-Eppendorf) and were grown in phenol red-free high-glucose 
Dulbecco’s modified Eagle’s media (DMEM, Invitrogen) supplemented with 10% fetal 
bovine serum (Thermo Scientific), 1% sodium pyruvate, and 1% 
penicillin/streptomycin (Sigma-Aldrich) at 37°C. For estrogen induction, cells were 
deprived of hormones by treating them with DMEM media supplemented with 5% 
charcoal-dextran-treated fetal bovine serum (CSS; Biochrome), 1% sodium pyruvate, 
and 1% penicillin/streptomycin after 24 hr of growth. After 48 hr, cells were treated 
with 10 nM 17 β-estradiol (Sigma-Aldrich) and/or 1 µM ICI-182,780 (Fulvestrant) for 
2 hr. MCF10A cells were kindly provided by M. Oren (Weizmann Institute of Science, 
Israel) and were grown in phenol-red free DMEM/F12 medium supplemented with 
5% horse serum, 20 ng/mL epidermal growth factor, 0.1 µg/mL Cholera toxin, 10 
µg/mL insulin, 0.5 µg/mL hydrocortisone, 1% penicillin/streptomycin at 37°C. 
Protein isolation and Western blotting 
 As mentioned previously (Bedi et al., 2015; Nagarajan et al., 2014), whole cell 
protein lysates were prepared from MCF7 and MCF10A by incubating the cells in 
Radioimmuno-precipitation buffer (RIPA buffer - 1% (v/v) NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS in 1X PBS along with protease inhibitors: 1 mM 
Pefabloc, 1 ng/μL Aprotinin/Leupeptin, 10 mM β-glycerophosphate and 1 mM N-
ethylmaleimide) for 10 minutes and scraping the cells if required. Samples were 
briefly sonicated to release the chromatin associated proteins.  Samples were 
heated along with SDS loading dye by incubating them at 95°C for 5 -10 minutes. 
These samples were run in a SDS- Polyacrylamide Gel Electrophoresis (PAGE). 
Proteins were visualized by Western blotting with following antibodies and dilutions: 
β-actin, I-19, sc1616, HRP-conjugated, 1:5000, Santa Cruz; ERα, HC-20, sc-543, 
rabbit polyclonal, 1:1,000, Santa Cruz; H4K12ac, ab61238, rabbit polyclonal, 1:1000, 
abcam; H3, ab10799, mouse monoclonal, 1:5000, abcam.  β-actin was used as 





Western blot was done using Biorad Image Lab 5.2 software and H4K12ac was 
normalized with H3.  
ChIP-Seq, RNA-seq and raw data information 
Chromatin immunoprecipitation of H4K12ac was performed as described 
previously (Nagarajan et al., 2014) using anti-acetyl-histone H4 (Lys12) (07-595; 
EMD Millipore) and negative control IgG (ab37415; abcam) with 10 min crosslinking 
with 1% formaldehyde. The following primers were used for ChIP-qPCR analyses: 
GREB1 TSS  Forward - 5’-GCCAAATGGAAGAAGGACAG-3’, Reverse - 5’-
ACCACCTACCTCCAGTCACC-3’; CXCL12 TSS Forward – 5’-
GCAGTGCGCTCCGGCCTTT-3’, Reverse - 5’-CCTCACTGCAGACCGGGCCA-3’;  
XBP1 TSS Forward – 5’-ATCCCCAGCTCTGGTCATCT-3’, Reverse- 5’-
GCCCAGGGCTCTTTTCTGTA-3’; RPLP0 TSS Forward – 5’-
CTTCGCGACCCTACTTAAAGG-3’, Reverse – CAATCAGAAACCGCGGATAG-3’; 
GAPDH TSS Forward – 5’-CGGCTACTAGCGGTTTTACG-3’, Reverse – 5’-
AAGAAGATGCGGCTGACTGT-3’; hnRNPK adjacent to TSS Forward- 5’- 
TCCACGAGGTCCCTAGTTCC-3’, reverse – 5’- GCCATTTCCCTGAGCGTGTA-3’. 
 ChIP-seq libraries were made using the NEBNext Ultra DNA library 
preparation kit according to the manufacturer’s instructions (Nagarajan et al., 2014). 
The size range of the libraries was verified to be 250-600 bp using Bioanalyzer 2100. 
75 bp single-ended tags were sequenced with single indexing using Illumina 
NextSeq 500 (XCelris Genomics, Ahmedabad, India). Previously published data for 
BRD4, H2Bub1 and ERα ChIP-seq as well as RNA-seq are available from the NCBI 
Gene Expression Omnibus (GEO) (GSE55921, GSE55922) (Nagarajan et al., 2014). 
Raw data for FOXA1, H3K4me3, H3K27me3 (Joseph et al., 2010), H3K27ac 
(Theodorou et al., 2013), RNAPII (Welboren et al., 2009), and GRO-seq (Hah et al., 
2013) were downloaded from the European Nucleotide Archive. Normalization of 
RNA-sequencing read counts for each gene was performed using DESeq (Anders 
and Huber, 2010). 
Bioinformatic analyses 
ChIP-seq reads were mapped to the human reference genome (UCSC HG19) 





converted into bam files by SAMtools (Li et al., 2009). DeepTools (Ramírez et al., 
2014) was used to create bigwigs by normalizing the ChIP-seq sample with the input 
samples of each cell line and obtaining the ratio of the reads using bamCompare 
function.  Normalization was done using read counts of each ChIP-seq sample. 
Average density was calculated using computeMatrix function in deepTools 
surrounding TSS (plus 3 kb) or ERE (±1.5 kb). The Heatmapper function from 
deepTools was used to create heatmaps and average profiles. TSS and gene body 
coordinates for hg19 were obtained from UCSC Table Browser (Karolchik et al., 
2004). Estrogen-upregulated, downregulated and BRD4 siRNA downregulated and 
BRD4-independent genes were categorized from our previously published RNA seq 
datasets (Nagarajan et al., 2014). Distal EREs or H3K27ac-positive regions were 
obtained from ERα and H3K27ac binding sites respectively which were not within 
gene bodies and regions 5 kb upstream or downstream of them. TSS and 3 kb 
downstream regions were used for TSS-based correlation plots and 1.5 kb up- and 
downstream of distal EREs for distal ERE-based correlation plots. Correlation plots 
were made using the bamCorrelate function in deepTools. Groups based on 
H4K12ac signals were determined using k-means clustering in heatmapper function 
of deepTools. Molecular signature database (MSigDB) (Liberzon et al., 2011) 
pathways whose target genes are enriched for BRD4 or specific histone 
modifications were identified using the Genomic Regions Enrichment of Annotations 
Tool (GREAT) (McLean et al., 2010). Boxplots and scatterplots were made using R 
for statistical computing. The Mann-Whitney test was used to calculate the statistical 
significance for boxplots. Pearson correlation coefficient values were calculated 
using R for scatter plots and p-values were calculated using two-tailed probability 
test.  
Accession Numbers 
The NCBI Gene Expression Omnibus accession number for H4K12ac ChIP-
seq data reported in this paper is GSE65886. 
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2.2.1. Supplementary information 
 
Figure 2.II.S1. (A) Average genomic binding profiles of H4K12ac around TSS and 3 kb upstream and 
downstream of all the genes under vehicle (Veh) and estrogen-treated (E2) conditions. The X-axis 
shows the distance from the TSS of the genes in kilobase pairs. TSS is indicated by a black dotted 
line. (B) Heatmaps showing genomic binding profiles of H4K12ac around TSS and 3 kb upstream and 





heatmap represents TSS. Color key of the heatmaps is shown on the side.  (C) Correlation plot 
showing the heatmap with the Pearson’s correlation coefficient values for H4K12ac, BRD4, H3K27ac, 
H3K4me3, H2Bub1, GRO-seq, RNAPII and H3K27me3 on TSS and 3 kb downstream region of all 
genes. Color key of the heatmap is shown at the bottom of the plot. (D) Average genomic binding 
profiles of H4K12ac around TSS and 3 kb upstream and downstream of estrogen-downregulated 
genes under vehicle (Veh) and estrogen-treated (E2) conditions. The X-axis shows the distance from 
the TSS of the genes in kilobase pairs. TSS is indicated by a black dotted line. (E) Heatmaps showing 
genomic binding profiles of H4K12ac around TSS and 3 kb upstream and downstream of all genes 
under vehicle (Veh) and estrogen-treated (E2) conditions. Center of the heatmap represents TSS. 
Color key of the heatmaps is shown on the side.  (F) Heatmaps showing genomic binding profiles of 
H3K27ac, H4K12ac with estrogen treatment (H4K12ac E2) and without estrogen treatment (H4K12ac 
Veh), BRD4, nascent RNA transcription (GRO-seq), RNAPII, H2Bub1, H3K4me3 and H3K27me3 
around TSS and 3 kb upstream and downstream of estrogen-induced genes. Density of the signals is 
arranged according to average H3K27ac signals from high to low. Center of the heatmap represents 







Figure 2.II.S2: (A) Heatmaps showing genomic binding profiles of H3K27ac, H4K12ac with estrogen 
treatment (H4K12ac E2) and without estrogen treatment (H4K12ac Veh), BRD4, nascent RNA 
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transcription (GRO-seq), RNAPII, ERα, FOXA1 and H3K27me3 around distal EREs and 5 kb 
upstream and downstream with all estrogen-treated (E2) conditions. Density of the signals is arranged 
according to H3K27ac signals from high to low. Center of the heatmap represents center of the distal 
ERE region. Color key of the heatmaps is shown on the side. (B) Venn diagram showing the overlap 
of distal binding regions of H3K27ac (red), H4K12ac (green) and BRD4 (blue). (C)  GREAT analyses 
on distal regions which oveelpas with H3K27ac, H4K12ac and BRD4 occupancy. The names of the 
Molecular signature database (MSigDB) pathways are denoted with their –log 10 binomial p-values. 







Figure 2.II.S3. Scatterplots showing the relationship between various ChIP-seq signals (H4K12ac, 
H3K4me3, BRD4, H2Bub1, RNAPII, GRO-seq, H3K27ac, H3K27me3, logarithmic fold changes of 
siBRD4 compared to siCont (Log2FC)) and absolute gene expression in logarithmic values for 
estrogen upregulated genes. Each dot in the plot represents a single gene. Red line indicates the 
correlation. 
 
Figure 2.II.S4. Pearson correlation coefficient (R) values were shown in tables representing the 
relationship between various ChIP-seq signals (H4K12ac, H3K4me3, BRD4, H2Bub1, RNAPII, GRO-
seq, H3K27ac, H3K27me3, logarithmic fold changes of siBRD4 compared to siCont (Log2FC)) and 









Efficient transcription requires a complex integration of several chromatin-
associated factors, histone modifications and transcriptional machinery in order to 
facilitate its temporal and spatial regulation. Several transcription factors have been 
shown to be important in stimulus-dependent transcription and these factors were 
observed to be recruited by specific stimuli. The recruitment of transcription factors 
determines cell type-specific function. The binding of these factors can also regulate 
or be regulated by the presence of histone marks. The tight cross-regulation of the 
histone marks may coordinate active transcription in response to various signaling 
pathways and inducible gene expression systems. Thus the histone marks and 
transcription factors can efficiently modulate stimulus-associated transcription.  
 
Figure 3.1. Mechanism of histone acetylation and BRD4 in regulating estrogen-induced 
transcription. Binding of ERα to EREs recruits HATs to promote BRD4 binding to the chromatin. This 
activates CDK9 to phosphorylate RNAPII at Ser2 residues and subsequently histone 
monoubiquination. ER – ERα; HAT - histone acetyltransferase; ac - histone acetylation; S2P - RNAPII 
p-Ser2; Ub - H2Bub1. 
 In our study, we demonstrated the importance and the association of 
H4K12ac and BRD4 in regulating estrogen-dependent transcription (Figure 3.1) 
(Nagarajan et al., 2014, 2015). Notably, we attempted to elucidate the mechanisms 
stimulated by the association of H4K12ac and BRD4 in estrogen induction. 
According to our model, estrogen treatment induces the ERα-dependent recruitment 
of histone acetyltransferases (HATs), which promote H4K12 acetylation and 
subsequent BRD4 recruitment to promoters and conserved EREs, especially on 






dependent phosphorylation of RNAPII and monoubiquitination of H2B across gene 
bodies. More importantly, H4K12ac and BRD4 associate with the occupancy of ERα, 
FOXA1, RNAPII and H3K27ac on active distal enhancers and regulate the 
production of eRNAs from these regions. Our findings significantly support the recent 
evidences showing the importance of BRD4 in controlling the nuclear hormone-
dependent transcriptional function in castration-resistant prostate cancer and 
tamoxifen-resistant breast cancer which were published while our manuscript was 
under review (Asangani et al., 2014; Feng et al., 2014).  Deeper analyses of these 
mechanisms underlying the regulation of estrogen-dependent transcription improve 
our understanding of transcriptional machinery involved in stimulus-induced 
transcription and the cell-type specific role of histone acetylation and BRD4 in 
promoting signal-induced transcription.  
3.1. Mechanisms of H4K12ac and BRD4 in regulating transcription 
3.1.1. The BRD4 , CDK9 and RNF40 axis in estrogen-induced transcription 
Our studies identified a novel association of H4K12ac and BRD4 in regulating 
RNAPII recruitment and/or phosphorylation and H2B monoubiquitination during 
estrogen-induced transcription. Hence this supports a tight coupling of histone 
acetylation, BRD4 recruitment, P-TEFb, RNF20/40 and H2Bub1 in a coordinated 
axis in the transcription of estrogen-stimulated genes. This hierarchical pathway is 
partially shown to be associated with several signal-induced transcriptional 
mechanisms or cellular differentiation (Ai et al., 2011; Karpiuk et al., 2012; 
Lamoureux et al., 2014). However, its complete association is mostly unknown in 
other contexts. The established paradigm in our study supports the association of P-
TEFb and H2Bub1 in regulating the transcriptional outcome during estrogen 
stimulation (Wittmann et al., 2005; Ogba et al., 2008; Prenzel et al., 2011; Mitra et 
al., 2012; Sengupta et al., 2014). Moreover, our results further support a role of 
BRD4 in promoting the cell-fate specific decisions or processes via regulating 
transcriptional pathways (Chiang, 2014; Liu et al., 2014; Micco et al., 2014; Xu and 
Vakoc, 2014).  
CDK9 phosphorylates RNAPII at Ser2 residues and facilitates transcription 





the WAC/RNF20/40 complex and leads to H2B monoubiquitination across gene 
bodies. Decreased RNAPII phosphorylation and H2B monoubiquitination following 
BRD4 depletion/inhibition and the positive correlation of H4K12ac with H2Bub1 
illustrate H4K12ac and BRD4 as upstream regulators of CDK9- and RNF20/40-
associated transcriptional elongation and further confirms their importance in the 
involvement of the H4K12ac – BRD4 – P-TEFb – RNF40 – H2Bub1 model. 
Furthermore, this supports the role of transcriptional elongation in mediating 
estrogen-regulated transcription (Aiyar et al., 2004; Kininis et al., 2009). Interestingly, 
our study also uncovers an important role of BRD4 in the recruitment of RNAPII on 
enhancers and histone monoubiquitination on the gene bodies which exhibit de novo 
recruitment of RNAPII upon estrogen treatment.  
A previous study from our group showed that RNF40 depletion stimulates 
estrogen-independent growth by activating EGFR-dependent kinase pathways 
(Prenzel et al., 2011). Moreover, overexpression of Ubiquitin-Specific Protease-22 
(USP22), which possesses H2B deubiquitinase activity, was also shown to promote 
androgen-dependent as well as androgen-independent growth in castration-resistant 
prostate cancer cell lines by facilitating AR expression and its activity and USP22 is 
also highly expressed in castration-resistant prostate cancer (Schrecengost et al., 
2014). Interestingly, our work highlights the involvement of BRD4 in ERα-dependent 
growth in vitro and in vivo (Figure 2.I.2). Altogether these suggest a strong 
connection between BRD4 and H2B ubiquitination in determining estrogen 
dependency by the cells.  
An important role of CDK9 and Cyclin T1 was shown to be important for 
estrogen-regulated gene expression (Wittmann et al., 2005; Sharp et al., 2006; Mitra 
et al., 2012). This supports a mechanism whereby BRD4 could potentially associate 
with and activate a P-TEFb-ERα complex and thus promote ERα-associated 
transcriptional pathways. An examination of the amino acid sequence of BRD4 
shows that BRD4 contains a possible estrogen Receptor Interaction Domain, LXXLL 
motif (LQYLL from 63-67 amino acid residues) within its first bromodomain (Results 
unpublished). Consistently, a weak BRD4-ERα interaction was reported using 
biochemical overexpression and immunoprecipitation analyses (Wu et al., 2013). 





decrease of H4K12ac following treatment with a pure ERα-antagonist (Figure 2.II.5) 
strongly suggests a coordinated functional interaction of H4K12ac and physical 
interaction between BRD4 with ERα. Altogether these results support a direct or 
indirect association/interaction of H4K12ac-BRD4-CDK9 with ERα to elicit their effect 
on the estrogen-specific gene expression.  
3.1.2. BRD4 recruitment is associated with histone acetylation downstream of 
initial active enhancer events 
Global histone acetylation was previously shown to correlate with the tumor 
phenotype and survival in breast cancer (Elsheikh et al., 2009). BRD4 is tightly 
associated with binding to acetylated chromatin via bromodomains. Several studies 
show that BRD4 specifically recognizes histone acetylation at H4K5, 8, 12 and 16 
(Chiang, 2009; Umehara et al., 2010; Filippakopoulos et al., 2012; Zhang et al., 
2012a). Structural and biochemical analyses demonstrated the differential binding of 
BD1 and BD2 of BRD4 to histone acetylation (Filippakopoulos et al., 2012). 
Interestingly, H4K12ac is bound by both the bromodomains. Even though the 
mechanistic link between H4K12ac and BRD4 is well established, their functional 
relevance was poorly known. Our study shows a clear correlation of H4K12ac and 
BRD4 occupancy on estrogen-dependent promoters as well as enhancers to 
regulate target gene expression.  
H4K12ac was previously shown to be dynamically regulated upon estrogen 
treatment on various estrogen-induced genes (Eeckhoute et al., 2007; Lupien et al., 
2009, 2010). This mark can be catalyzed by several HATs including p300 and CBP 
which are considered to be important coactivators of ERα-regulated transcription. 
Furthermore, signal-induced H4K12ac has been implicated in the enhancer activity 
along with H4K16ac (Zippo et al., 2009). Our findings further validate the importance 
of H4K12ac in estrogen-regulated gene induction via occupying enhancers and 
suggest a possibility of a general function in stimulus-dependent transcriptional 
regulation. Further analyses of the association of H4K12ac with RNAPII recruitment 
and H2Bub1 reveal a potential role of H4K12ac in regulating the transcriptional 





Even though BRD4 preferentially binds to H4 acetylated residues, the strong 
correlation of BRD4 and H4K12ac with H3K27ac and increased enrichment of both 
H4K12ac and H3K27ac after estrogen treatment infers a possible functional cross-
talk between H3K27ac and H4K12ac in promoting estrogen-dependent transcription. 
Our studies show that BRD4 and H4K12ac correlate with H3K27ac on both 
promoters and enhancers. This supports the previously reported link between BRD4 
and H3K27ac in facilitating gene transcriptional activity (Zhang et al., 2012a). 
Consistent with the importance of H4K12ac in regulating the recruitment of BRD4 
rather than H3K27ac, our results show that BRD4 occupancy is more closely 
correlated with H4K12ac than H3K27ac (Figure 2.II.1-2). Moreover, the increased 
occupancy of H3K27ac after estrogen treatment is not affected by the inhibition of 
BRD4 binding which supports the fact that BRD4 binding occurs downstream of 
histone acetylation events. More importantly, ERα binding is more closely associated 
with H4K12ac and BRD4 than with H3K27ac. This may further support an essential 
function of BRD4 and H4K12ac in regulating the enhancer activity in estrogen-
responsive systems.  
3.1.3. H4K12ac and BRD4 correlate with enhancer activity and eRNA 
production 
Apart from the involvement of BRD4 and CDK9 in transcriptional elongation, 
these proteins have also been shown to be associated with enhancer activity (Hah et 
al., 2013; Lovén et al., 2013). H4K12ac occupancy at EREs was also shown of both 
conventional ERα binding sites as well as for tamoxifen-resistant binding (Lupien et 
al., 2009, 2010). Our results show that H4K12ac and BRD4 are essential for 
promoting the enhancer activity of EREs. More importantly, we show that BRD4 
depletion or inhibition results in decreased eRNA transcription particularly from 
ERα/FOXA1-bound EREs which are enriched for H4K12ac as well as RNAPII and 
BRD4. This supports a previously reported role of CDK9 and BRD4 inhibition in 
controlling the transcription of estrogen-induced and active macrophage associated 
eRNAs respectively (Hah et al., 2013; Kaikkonen et al., 2013). Our results further 
provide a mechanistic insight into the regulation of enhancer activity by histone 
acetylation and BRD4. Interestingly, another study showed that inhibition of eRNA 





(RNAPII PSer5) and MED1 occupancy on androgen receptor-bound enhancers 
(Hsieh et al., 2014). Given the tight association of the Mediator complex and BRD4 
(Wu and Chiang, 2007; Chiang, 2009; Lovén et al., 2013), this study supports our 
data and suggests that BRD4 plays a central role in regulating nuclear hormone 
receptor-dependent eRNA production. The observed BRD4-specific regulation of 
eRNA synthesis and polymerase recruitment on ERα-bound enhancers was also 
further verified by another recent study which shows that BRD4 is required for the 
elongation of eRNA transcripts from the enhancers with hyperacetylated 
nucleosomes (Kanno et al., 2014). Overall H4K12ac and BRD4 can very likely 
regulate genome-wide production of enhancer-derived transcripts and facilitate the 
enhancer activity to help in the determination of cell-specific functions.  
A recent study elucidated eRNA transcription as a very early response 
following induction with various stimuli (Arner et al., 2015). However, our studies 
show that BRD4 inhibition does not affect the early chromatin-associated events of 
enhancer activation, but inhibit estrogen-induced eRNA transcription. Another study 
shows that establishment of an enhancer (ie., H3K4me2 occupancy) is regulated at 
the level of elongation of eRNA transcription by CDK9 and BRD4 inhibition, but 
inhibition of eRNA transcription did not affect H3K4me2 deposition (Kaikkonen et al., 
2013). This suggests a hierarchical mechanism of BRD4 and CDK9 activity in 
regulating eRNA transcription which could be an intermediate event which must be 
further elucidated to achieve a clear understanding of eRNA-driven establishment of 
enhancers and regulation of enhancer activity.  
3.1.4. BRD4 recruits RNAPII and can release pausing of RNAPII  
Previous evidences described the coordinated function of BRD4 and CDK9 in 
regulating the phosphorylation events of RNAPII across gene bodies in order to 
control and coordinate transcriptional elongation with cotranscriptional processes 
(Zhang et al., 2012a; Patel et al., 2013). Consistently, our results uncover a likely 
role of BRD4 in the release of paused polymerase and efficient elongation in the 
context of ERα-dependent transcription. As described before, estrogen-regulated 
transcription is controlled by the phosphorylation of RNAPII and NELF complex 
proteins (Aiyar et al., 2004; Kininis et al., 2009). However, the regulatory 





pausing on enhancers are poorly understood. We showed that inhibition of 
enhancer-associated BRD4 binding affects RNAPII phosphorylation on individual 
EREs (Figure 2.I.4K). This was also supported by recent studies which show that 
BRD4 association on enhancers is involved in the transcriptional pause release of 
polymerase on the proximal promoter regions as well as enhancers and helps in the 
efficient transcription of mRNAs and eRNAs (Liu et al., 2013; Kanno et al., 2014). In 
addition to the effect on elongation-specific phosphorylation of RNAPII on 
enhancers, our studies surprisingly show that the recruitment of RNAPII to a subset 
of EREs is affected by BRD4 inhibition which further affects eRNA production at 
these distal regions (Figure 2.I.4J-L). Altogether, these findings suggest a novel 
mechanism where apart from releasing poised polymerase from the proximal 
promoters, BRD4 is involved in both the recruitment of RNAPII as well as its release 
from transcriptional pausing on enhancers and thereby promotes elongation of eRNA 
transcripts following estrogen stimulation. Considering the absence of RNAPII 
phosphorylation at Ser2 residues (Koch et al., 2011; Lam et al., 2014) and H2Bub1 
on enhancers which was observed in our study (unpublished results), these findings 
also proposes a unique process of transcriptional elongation which can likely be 
involved in the activation of enhancers.   
3.1.5. BRD4 acts downstream of initial enhancer activation events 
ERα-dependent transcription is influenced by the occupancy of active 
enhancer marks like H3K27ac and recruitment of several transcription factors and 
cofactors like FOXA1, ERα, p300/CBP, Cohesin complex, etc., on the corresponding 
EREs upon estrogen treatment. These events can happen very early before or 
during estrogen treatment and play an essential role in promoting enhancer-driven 
transcription probably by mediating enhancer-promoter interactions. Interestingly, 
our report shows that BRD4 is not required for these events. This suggests a 
downstream function of BRD4 in regulating ERα-dependent transcriptional pathways 
which does not affect the initial events which are important for epigenetically 
activating enhancers.  
An important mechanism by which ERα promotes transcription via enhancers 
is that it nucleates changes in higher order chromatin structure and brings enhancers 





et al., 2010). BRD4 and CDK9 were shown to be associated with Mediator complex 
proteins suggesting an important role in long range chromosomal interactions (Wu 
and Chiang, 2007; Chiang, 2009; Donner et al., 2010; Lovén et al., 2013; Allen and 
Taatjes, 2015). The CDK8 subunit of the Mediator complex interacts with CDK9 and 
promotes the recruitment of P-TEFb to facilitate RNAPII phosphorylation (Donner et 
al., 2010; Ebmeier and Taatjes, 2010; Galbraith et al., 2013; Allen and Taatjes, 
2015). Surprisingly, on a subset of ERα- and H3K27ac-occupied EREs, BRD4 
inhibition does not affect the estrogen-induced occupancy of the Cohesin complex 
subunit RAD21. This is consistent with another study which utilized 3C analyses to 
show that CDK9 inhibition does not impair the estrogen-induced chromosomal 
looping and other initiation events associated with eRNA-producing enhancers (Hah 
et al., 2013). Moreover, proteasomal inhibition using Bortezomib decreased 
estrogen-regulated transcription, whereas it had no effect on estrogen-induced 
looping events (Prenzel et al., 2011). All these studies further validate our data 
showing that BRD4 binding occurs downstream of early events of enhancer 
activation and probably does not affect chromosomal looping despite its association 
with the Mediator complex.  
3.1.6. BRD4 can facilitate chromatin opening  
A significant correlation of BRD4 with DNase hypersensitive sites occupying 
estrogen-responsive gene promoters and enhancers opens the possibility that BRD4 
could be involved in the opening of the chromatin (Figure 2.I.3E, 2.I.4E). Our studies 
reveal a potential role of BRD4 in bringing the chromatin to an elongation-favorable 
open state by promoting histone monoubiquitination across gene bodies in order to 
facilitate transcription (Figure 2.I.3C). Furthermore, Formaldehyde-Assisted Isolation 
of Regulatory Elements (FAIRE) analyses on MCF7 cells revealed that BRD4 
inhibition results in less frequency of open chromatin on ERα-bound enhancers 
(unpublished results). This further substantiates the role of BRD4 in regulating the 
opening of chromatin.  
Another possible mechanism which could be involved in the BRD4 associated 
opening of chromatin is the interaction of BRD4 with the SWI/SNF chromatin 
remodeling complex and their co-occupancy on enhancers (Shi et al., 2013). The 





Binding of the SWI/SNF complex to acetylated chromatin may be coordinated by 
BRD4 binding because both of these proteins contain bromodomains and H4K12ac 
may influence the binding of SWI/SNF to the chromatin. Given the important role of 
SWI/SNF subunits in estrogen-stimulated transcription and their association with 
H2B monoubiquitination (García-Pedrero et al., 2006; Green and Carroll, 2007; 
Shema-Yaacoby et al., 2013), BRD4 and the SWI/SNF complex may coordinate with 
histone acetylation and monoubiquitination to promote chromatin remodeling and 
estrogen-regulated transcription.  
3.1.7. Histone acetylation and BRD4 can coordinate transcriptional assembly 
turnover  
Estrogen-regulated transcription involves rapid and dynamic changes in the 
assembly of transcriptional machinery in order to regulate the temporal 
transcriptional activation in estrogen stimulation (Shang et al., 2000; Métivier et al., 
2003, 2006; Green and Carroll, 2007). This requires the coordinated activity of an 
intricate network of complex association and disassociation of transcriptional 
coactivators, chromatin remodelers and histone marks (Voss and Hager, 2014). 
Notably, our data uncover a low occupancy of H4K12ac, RNAPII and H2Bub1 
adjacent to the gene promoters which are dependent upon BRD4 compared to the 
genes which do not require BRD4 for their expression (Figure 2.II.3). This may 
suggest that genes which display rapid regulation of gene expression dependent 
upon BRD4 have lower occupancy of active marks which may coordinate a faster 
response. This may enable a dynamic mechanism of transcriptional assembly and its 
turnover which could be needed for the fast and precise fine-tuning in the temporal 
transcriptional activation upon estrogen response. Moreover, the rapid reduction of 
H4K12ac after ERα antagonist treatment further supports the dynamic nature of 
H4K12ac and BRD4 and their role in determining the extent and the level of 
increased gene expression.  
A complex of proteins exhibiting transcriptionally contradictory functions would 
be ideally suited to facilitate cyclical activity during transcription. An example is the 
Spt-Ada-Gcn5 acetyltransferase (SAGA) complex which contains both acetylating 
activity in  GCN5 as well as deubiquitinating activity of H2B via the USP22 subunit 





chromatin and can also associate with an NCOR-HDAC complex, although this 
connection is not well-understood (Underhill et al., 2000). Due to their possession of 
oppositely functioning subunits, these complexes can be involved in the temporal 
and dynamic regulation of induced gene activity. This effect may help to enable a 
rapid response to a decreased presence of the activating signal such that when the 
signal is no longer present, the deubiquitination and deacetylation would enable a 
pause in the expression by stimulating the cycling of the epigenetic status of the 
gene. Surprisingly, H2B ubiquitination and deubiquitination may be coordinated 
during gene activation such that both are required for the activation of some genes( 
Johnsen, 2012). Consistently, an earlier doctoral student in the Johnsen group 
demonstrated that depletion of either RNF40 or USP22 elicits a similar phenotype in 
mammary epithelial cells in vivo and in vitro (Bedi, 2015 Dissertation). This supports 
the necessity of addition or removal of active transcriptional marks or factors for the 
rapid turnover to maintain the subsequent rounds of transcription upon dynamic 
signaling. Thus, these complexes can coordinate with H4K12ac and H2Bub1 due to 
their previously studied physical and functional interactions and could be commonly 
involved in various scenarios in order to control the dynamic nature of gene 
transcription (Johnsen, 2012; Shema-Yaacoby et al., 2013). 
3.2. Targeting histone acetylation and BRD4 in the treatment of breast cancer 
Overall our studies describe a potential important role of H4K12ac and BRD4 
in coordinating various chromatin-associated during estrogen-induced transcription. 
Deregulation of these mechanisms results in altered transcriptional responses and 
control the biological effects of various signaling pathways. BRD4 activity has been 
implicated in the development of various diseases, most importantly cancer (Zuber et 
al., 2011; Herrmann et al., 2012; Lockwood et al., 2012; Chapuy et al., 2013; 
Asangani et al., 2014; Bhadury et al., 2014; Feng et al., 2014; Fiskus et al., 2014). A 
deeper understanding of the association of histone acetylation and BRD4 in 
transcriptional regulation could provide a potential rationale for utilizing BRD4 or HAT 
inhibitors as specific therapeutic targets for various cancers. Given the recent 
availability of various specific inhibitors of BRD4, such an approach may represent a 






Therapeutic approach of using BRD4 inhibition as a possible therapeutic 
approach is supported by the fact that some BRD4 inhibitors have already entered 
clinical trials. OTX015 is currently in phase 1B trial for advanced solid tumors 
(Clinicaltrials.gov Identifier: NCT02259114) and in phase 1-associated dose finding 
study against hematological malignancies (NCT01713582). IBET-762 is in phase 1 
trials for NUT-midline carcinoma (NCT01587703) and relapsed, refractory 
hematologic malignancies (NCT01943851). In another context, RVX-208 
successfully completed phase 2 trials against diabetes, coronary artery disease, 
atherosclerosis and dyslipidemia (NCT01728467, NCT01058018 and 
NCT00768274). Based on the early use of these inhibitors in clinical trials, our 
studies utilizing BRD4 inhibition as a strategy to control the estrogen-dependent 
growth in breast cancer cells in vitro and uterine growth in vivo may provide a 
foundation for its use in breast cancer patients (Figure 2.I.2). By developing 
bromodomain-specific inhibitors, recent evidences demonstrate different functions of 
BD1 and BD2 of BET family of proteins (Picaud et al., 2013b). The acetylation 
binding pattern of each bromodomain was also recently shown to be unique for 
several bromodomain-containing proteins (Filippakopoulos et al., 2012). Thus, 
understanding the possible distinct functions of different bromodomains in the 
context of estrogen-dependent transcriptional pathway may further improve the 
specificity and efficacy of BET inhibitor-based therapeutic approaches.  
Similar to the growth inhibitory role of BRD4 inhibition in regulating ERα-
dependent transcription in tamoxifen-resistant breast cancers (Feng et al., 2014), 
another recent study observed the efficient inhibition of proliferation by JQ1 using  in 
vitro and in vivo models of everolimus (mTOR inhibitor which inhibits estrogen 
independent growth)-resistant ER-positive breast cancers (Bihani et al., 2015). 
Moreover, another study reported an interaction of BRD4 with diacetylated TWIST, a 
transcriptional factor involved in epithelial-to-mesenchymal transition and proposed 
to play an important role in tumor metastasis (Yang et al., 2004), thereby providing a 
rationale and independent mechanism for targeting BRD4 in basal-like breast 
cancers (Shi et al., 2014, 2015).  
Differential acetylation pattern on enhancers likely determines cell-specific 





induced transcription, our study uncovers the role of H4K12ac in determining 
estrogen-dependent enhancers. Considering the differential association of 
acetylation marks with different bromodomain-containing proteins (Filippakopoulos et 
al., 2012), our study further supports a specific strategy of targeting various 
diseases. However, using HDAC inhibitors may inappropriately hyperacetylate and 
activate enhancers which should not be active and thereby lead to adverse effects. A 
deeper understanding of the specific association of histone acetylation with 
enhancers and the effect of HDAC inhibition in these cases would be therefore 
necessary before utilizing HDAC inhibitors for treating ERα-positive breast cancer 
patients. Our attempt to study a single acetylation mark in a cell-specific function 
which can be deregulated in disease furthers our knowledge about the role of 
specific histone acetylation events in facilitating cell-type specific transcriptional 
programs.  
 
Figure 3.2. Therapeutic targeting of the ERα-regulated transcriptional pathway by the 





the particular proteins or their inhibitors are involved in the inhibition of the pathway. Inhibitors of 
these proteins or processes are marked in blue. (Modified from Johnsen, 2012).  
In addition to estrogen induction, H4K12ac occupancy was also shown to be 
induced on the distinct ERα binding sites upon EGF signaling and implicated in the 
tamoxifen-resistant breast cancers (Lupien et al., 2010). Furthermore, a recent study 
shows that synergistic ERα degradation could be induced by JQ1 and Fulvestrant. 
This suggests a combinatorial effect in arresting tumor growth by increasing tumor 
sensitivity to growth inhibition and results in better survival in tamoxifen-resistant 
xenograft models (Feng et al., 2014). Similarly, our studies also show that prolonged 
BRD4 knockdown reduces ERα expression while short term BRD4 inhibition does 
not affect ERα mRNA or protein levels but still significantly inhibits estrogen-induced 
transcriptional pathways (Figure 2.I.S1J, 2.I.S4A). Considering the rapid reduction of 
H4K12ac by Fulvestrant in our study, this suggests a plausible role of  H4K12ac  
occupancy in the progression of tamoxifen-resistance which could be consistent with 
the role of BRD4 (Feng et al., 2014).  Consistently, HDAC inhibitors were shown to 
reverse tamoxifen/aromatase inhibitor-associated resistance in ER-positive breast 
cancers (Munster et al., 2011). This further supports an importance of histone 
acetylation in mediating tamoxifen-sensitivity in breast cancer. Furthermore, recent 
evidences show that HDAC inhibition acts synergistically with JQ1 in promoting 
apoptosis and tumor regression by affecting the same subset of gene targets 
synergistically (Bhadury et al., 2014; Fiskus et al., 2014). Mechanistically, this may 
mean that HDAC inhibition promotes hyperacetylation and likely makes the 
transcriptional machinery more sensitive to JQ1 inhibition. Hence, targeting histone 
acetylation and BRD4 could serve as a potential therapeutic strategy for the cells 
resistant to various treatments (Figure 3.2).   
However, studies also report a role of BRD4 in suppressing metastasis and 
the progression of advanced breast cancers, thereby suggesting another, opposing 
tumor-suppressor function of BRD4 (Crawford et al., 2008; Alsarraj et al., 2011; 
Fernandez et al., 2014). However, BRD4 inhibition by IBET-151 which was 
previously shown to reduce tumor growth of primary leukemic cell lines in xenograft 
models did not affect the pulmonary metastasis in metastatic lung models (Dawson 
et al., 2011; Alsarraj et al., 2013). Further analyses have shown that the short 





acetylated histone binding properties and promotes metastasis by interacting with 
metastasis associated proteins (Alsarraj et al., 2013). Moreover, the short isoform of 
BRD4 was also shown to inhibit the DNA damage response by interacting with the 
Condensin complex and maintain a closed chromatin context. Inhibition of BRD4 
along with radiation in various cancer cell lines resulted in the enhanced DNA 
damage response and survival of these cells (Floyd et al., 2013). From these 
studies, we can hypothesize that the spatial and nuclear distribution of BRD4 
isoforms will significantly impact the therapeutic targeting of cancers. Considering 
the association of loss of H2Bub1 and BRD4 in cancer progression, considerable 
care should be taken in analyzing the repertoire of BRD2/3/4 isoforms expressed in 
the tumor before treating them with BRD4 inhibitors.  
Overall our studies demonstrate a major attempt to understand the molecular 
epigenetic mechanisms promoting estrogen-induced transcription and proliferation or 
growth of breast and endometrial cancer cells. Given the importance of the 
H4K12ac-BRD4-P-TEFb-RNF40-H2Bub1 axis in estrogen-induced transcription, 
combination therapies inhibiting the function of individual protein involved in this 
paradigm may efficiently and specifically affect estrogen-dependent cancer 
progression (Figure 3.2). Consistently, the inhibitors available against these proteins 
were found to be effective in in vitro or in vivo models of induced gene transcription, 
and interestingly some of them were also successful with the combinatorial 
administration (Wakeling and Bowler, 1992; Prenzel et al., 2011; Munster et al., 
2011; Hah et al., 2013; Nagarajan et al., 2014; Schrecengost et al., 2014; Fiskus et 
al., 2014; Feng et al., 2014; Bhadury et al., 2014). Xenograft studies in mice using 
the administration of these inhibitors in combination would further support the utility 
of targeting histone acetylation and BRD4 in the treatment of breast cancer. 
Considering the possible CDK9-independent function of BRD4 in regulating ERα-
driven cancers, a therapeutic approach combining BRD4 inhibitors with CDK9 
inhibitors may potentiate the survival of patients. Altogether, our study would greatly 
help in the development of combinatorial therapies involving the modulation of 
histone acetylation and BRD4 inhibition as a potential specific therapeutic strategy 
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